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Abstract 
 
The dissertation details the experimental work on the attempt to develop rhenium(V)-
phthalocyanine complexes directly from its +7 oxidation state (perrhenate). Different 
reducing agents (PPh3, Na2S2O5 and NaBH4) were employed and consequently, different 
results were acquired, such as rhenium(V)-mediated oxidative hydrolysis of the 
phthalocyanines (Pcs), the formation of a rhenium-phthalocyanine complex and 
phthalocyanine-capped nanoparticles. The rhenium nanoparticles that were formed were 
optimized from a synthesis point of view and, cancer localizing ability of the rhenium 
nanoparticles was investigated. The complexes were synthesized through direct metalation of 
pre-formed metal-free phthalocyanines using the “cold isotopes” of the rhenium metal. 
Rhenium nanoparticles (Re NPs) were synthesized in aqueous saline medium so as to imitate 
the environment on which Re is produced from its reactor. The nanoparticles (NPs) were 
capped with phthalocyanines which were covalently biofunctionalized with a folic acid 
moiety to enhance the targeting ability of the Re NPs.  These NP systems were characterised 
with techniques such as ultraviolet-visible UV-Vis spectroscopy and transmission electron 
microscopy TEM.     
 
Cytotoxicity of the NPs was tested against four different cell lines and subsequently their 
cytotoxicity profiles were elucidated, and the profiles shown a dose-dependent 
responsealthough the results in some cell lines were unclear. Their fluorescence properties 
were also studied to provide photophysical information for investigation of their tumor 
localization using human cancer cells lines via confocal fluorescence microscopy studies. 
Particle size effect on localization of NPs was also investigated using confocal fluorescence 
and TEM. Two sizes were chosen (10 and 50 nm), and the smaller NPs (10 nm) were found to 
exhibit stronger fluorescence properties than the 50 nm NPs, and they were also found to 
have a better localization ability than the 50 nm NPs. Finally, their tumor and organ 
biodistribution studies will be carried out using micro-SPECT kits and model mice (using the 
“hot” isotopes in a radiopharmacy laboratory). 
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Chapter 1 
….. 
Introduction 
1.1 Motivation  
There are very few diseases that exasperate the instinctive terror of cancer. This is due to the 
atrocities presented by cancer to humanity since antiquity. Cancer is the second major cause 
of death in the United States and a major public health problem in many other parts of the 
world [1]. One in four deaths in the United States is due to cancer [1] and more than 14 
million people worldwide will be diagnosed with cancer this year [2]. In 1971, the President 
of the United States of America, Richard Nixon, formally declared war on cancer. Since that 
time, well over $105 billion has been spent on efforts to find “magic drugs” for cancer. David 
Nathan upholds, in his book The Cancer Treatment Revolution (published in 2007), the idea 
that there has been considerable progress towards finding cancer treatment.  
There is still a long way to go, since most of the conventional ways of treating cancer still 
present many shortcomings. Current research in the field of nuclear medicine continues to 
yield promising results. The task of nuclear medicine is to contribute to the diagnosis of 
disease or provide a therapy for disease states. In modern medicine, early diagnosis of 
diseases plays an important part in improving the life and reducing healthcare costs to 
society. Just as important, however, are the therapeutic treatments of patient’s diseases and 
the detection of the curative process in which nuclear medicine also plays a role.  
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1.2 Aetiology of cancer  
Cancer is the general term given to a pool of different diseases (i.e. breast cancer, skin cancer, 
lung cancer, colon cancer, prostate cancer, lymphoma, and others) that share a fundamental 
feature at cellular level, such as hysterical and abnormal cellular growth which can result in a 
lump or tumour (Figure 1.1). A tumour can either be benign (non-cancerous) or malignant 
(cancerous). Cancer cells evolve from normal cells. Normal cells require signals usually 
delivered by ligands (a molecule that binds to a receptor) to stimulate their growth and 
instruct them when to stop growing. These ligands can be in a form of growth factors or 
inhibition factors. The signals are transferred into the cell through proteins found on the cell 
surface called receptors. When the ligand binds to the receptors, the signal is sent into the 
intracellular domain to the nucleus of the cell, to stimulate the cell to grow and divide or to 
stop growing. In normal cells the production of cellular surface receptor proteins is limited by 
cellular restraints on gene expression and protein translation. 
 
Figure 1.1: Formation of tumour cells from the normal cells, and metastasis of cancer cells 
[3]. 
 In tumour cells, however, mutations in the genes encoding for the receptors disrupt this 
finely tuned regulation, and too many copies of this gene are produced, a phenomenon called 
gene amplification. This in turn leads to excessive transcription and production of too many 
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receptors, resulting in a higher than normal number of copies (known as overexpression of 
receptors) on the tumour cell surface. This gives the tumour cells increased potential to be 
triggered by ligands to the growth phase, the more the receptors the more binding sites there 
are for the ligands. The genetic alterations in the cancer cells not only lead to increased cell 
proliferation and growth, but also lead to a loss in apoptosis (programmed cell death); along 
with too much cell growth, there is too little cell death. This causes the tumour cells to suffer 
from the lack of oxygen, which causes the launch of the mechanism of metastasis. Metastasis 
is characterised by the ability of cancer cells breaking off from the “primary tumour” and 
spreading to another organ via the blood or the lymph system and forming new tumours 
(secondary tumours) far from the original tumour. The tumour blood vessels are highly 
disorganised with a high proportion of proliferating cells, increased tortuosity and relatively 
thin walled, leaky and less supporting pericytes. The pore size is between 100 and 780 nm 
while normal cells have less than 6 nm [4]. The latter can be exploited for cancer cell 
accumulation by nanoparticles.    
1.3 A brief history of cancer  
The Greek physician Hippocrates (460-370 BC) is accredited as the person who coined the 
term cancer, from a Greek word karkinos (meaning crab), but he was not the first person to 
encounter cancer. The first recorded case of cancer dates back to about 1600 BC by the 
Egyptian physician, Imohtep, who summed up the patient’s fate harshly: “For this, there is no 
treatment” [5]. Some of the earliest evidence of cancer is found in fossilized bone tumours 
and ancient Egyptian mummies [6]. Cancer existed silently in history since its first record in 
the Egyptian manuscripts until Herodotus (440 BC), a Greek historian who chronicled the 
account of the daughter of Cyrus and queen of Persia, Atossa, who, after noticing a tumour in 
her breast was excised by Demasitis, her Greek slave, a technique that was believed to be 
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effective at least to some extent. Till the 18th century, scientists and physicians alike were 
holding the belief that cancer was contagious and was spread through parasites [7].  It was 
only in the mid-20th century that the scientific community started understanding the chemistry 
and biology behind cancer with the discovery of DNA by Watson and Crick [8]. This 
discovery opened the doors for the development of new and promising techniques for cancer 
treatment.  
1.4 Evolution of cancer treatments 
The quest to find a cure for cancer has been a struggle and it has been evolving with the 
progression of science and technology. There have been many success stories in this field 
through collaboration across a vast array of different disciplines, ranging from biology, 
chemistry, physics, material science, nanotechnology, to name a few. When attempting to 
treat cancer, there are several factors that need to be taken into consideration, like cancer 
stage, type, patients’ general health and preference. There are many techniques that were 
developed throughout the centuries to combat cancer; they can be broadly divided into two 
groups as local and systemic therapies. 
1.4.1 Local therapies 
1.4.1.1 Evolution of cancer treatments: Surgery 
Throughout the history of cancer, until the 19th century, surgery was the sole therapeutic 
approach for cancer treatment and remains an effective treatment for many types of cancer 
today. It was not long after the discovery of cancer, that the ancient physicians and surgeons 
(i.e. Roman physician, Celsus) noticed the ability of cancer to return subsequently, after it 
was surgically removed [7], and there was no remedy for cancer once it metastasizes to other 
parts of the body.  Galen, another Greco-Roman physician, documented surgery techniques 
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for cancer. Galen held Hippocratic view on cancer; Hippocrates thought that the body had 4 
humors (body fluids): blood, phlegm, yellow bile, and black bile. He proposed that a 
disproportion of these humors with an excess of black bile in various body sites might cause 
cancer [9,10]. Galen’s medical theories we held as the “magna carta” in the ancient world 
and influenced Western medical science for more than 1,300 years. Although medicine 
advanced and prospered in some ancient civilizations, there was minute development in 
cancer treatment. This impairment in cancer treatment progression was the result of Galen’s’ 
belief that cancer was incurable. 
Although surgery was the predominant cancer treatment at the time, it was primitive and 
presented complications and blood loss. It wasn’t until the discovery of anaesthesia in the 19th 
century by Crawford Long that major advances in cancer surgery and surgeries in general 
were made. During this period, three prominent surgeons; Theodor C. Billroth in Germany, 
Sampson W. Handley in London, and William S. Halsted in Baltimore pioneered radical 
mastectomy (the removal of the entire tumour together with the lymph nodes around the 
tumour location), which was rooted in the belief that cancer spread outward by invasion from 
the original growth. It was an English surgeon, Stephen Paget, who discovered that cancer 
spreads through blood circulation. This discovery was an important component in 
understanding limitations of cancer surgery. It also led to the systematic treatment that is 
employed after the surgery so as to destroy the cells that may have spread throughout the 
body. 
1.4.1.2 Evolution of cancer treatments: Early radiation therapy 
The use of radiation for diagnostic and therapeutic applications for cancer treatment was 
explored shortly after the discovery of X-rays in 1896, by Wilhelm Conrad Roentgen, a 
German physicist. In its ‘infancy’ stage, radiation therapy was using radium with low-voltage 
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diagnostic technologies. It was discovered in France that, daily doses of radiation for several 
weeks increased the chances of curing cancer significantly. It was later shown that, as much 
as radiation can cure cancer it can also cause cancer as well. In the last quarter of the 20th 
century, with the knowledge of radiation physics and computers, it was possible to precisely 
direct radiation to the organ of interest. 
Although radiotherapy was used to describe cancer treatment that uses X-rays, today 
radiotherapy also include the use of gamma rays, protons and electron beams to destroy or 
damage the DNA of cancer cells, thus stopping them from dividing and growing. The 
radiation affects both cancer cells and normal cells, but normal cells repair faster than cancer 
cells. During this repair period, the patient can experience the side effects. It is normally used 
for several reasons, such as curative treatment, for controlling cancer cells (making them 
smaller and stopping them from growing and spreading), palliative treatment (to relieve 
symptoms, like pain or bleeding) and can be combined with other treatments for effective 
cancer treatment. 
Radiation is usually delivered in fractionated doses, like 180 to 300 cGY per day, 5 times a 
week for a course of 5-8 weeks. It can be administered externally (Teletherapy) or internally 
(Brachytherapy). Teletherapy requires the use of an instrument that directs radiation 
externally to the body. The instrument remains outside the body during the treatment, 
whereas in brachytherapy, the radiation source is placed inside the body or near cancer cells.  
To improve this technique, researchers have developed agents that can make cancer cells 
more sensitive to radiation, as compared to normal cells [11]. Another area focused on trying 
to find substances that can protect normal cells from radiation, [12].   
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1.4.2 Systemic therapy 
1.4.2.1 Evolution of cancer treatments: Chemotherapy 
The use of chemotherapeutic agents to treat diseases was pioneered by a German chemist, 
Paul Ehrlich in the early 1900s. He coined the term “chemotherapy” and defined it as the use 
of chemicals to treat diseases [13].  Ehrlich developed the first, but very primitive compounds 
to treat cancer, including alkylating agents and aniline dyes, with little success. He later wrote 
on the doorpost of his research laboratory “Give up all hope oh ye who enter” [13]. A few 
years later, George Clowes developed the first model in rodents to test chemotherapy drugs 
including Sarcoma 37 (S37), Sarcoma 180 (S180), Walker 256, and Ehrlich’s ascites tumour 
[13].  
It was only during World War II in 1943, in an accidental spill of mustard gas that the 
potential of mustard gas and other compounds that resemble it was observed. This incident 
encouraged two Yale pharmacologists, Goodman and Gilman, to experiment with nitrogen 
mustard gas in the quest to treat cancer. Initial experiments were done in mice; the results 
were promising. The compound was successfully employed to patients with lymphoma. The 
victory, however, was partial for it was later realized that the remissions turned were brief 
and incomplete, and this observation then led to the synthesis of other effective drugs like 
Cisplatin, Thiopurines, 5-Fluorouracil, Methotrexate, and Antitumor antibiotics. 
Chemotherapy drugs differ extensively and they are loosely grouped based on their chemical 
structure, mode of action and relationship to other drugs. Alkylating agents, for example, act 
by damaging the DNA (the genetic material of the cell) to control cell division. They are used 
to treat variety of cancer types, like lung, breast, lymphoma, multiple myeloma, Hodgkin 
disease, ovary, sarcoma and leukemia. Some of the alkylating agents include nitrosoureas, 
(e.g. lomustine and streptozocin), nitrogen mustards (like mechlorethamine and ifosfamide), 
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and platinum drugs (e.g. cisplatin, oxalaplatin). Others act by interfering with the enzymes 
that are involved in DNA replication; these include anti-tumour antibiotics and 
Topoisomerase inhibitors.  
The challenge with chemotherapy as a cancer treatment is the fact that the drugs are not 
specific, i.e. they target and damage any rapidly dividing cells, meaning both normal and 
cancer cells are affected. There are also drug resistance issues at the tumour level due to 
physiological barriers, drug resistance at cellular level and in distribution, biotransformation 
and clearance of anticancer drugs in the body, that are associated with chemotherapy drugs 
[14]. Hence the side effects associated with chemotherapy. Chemotherapy also increases the 
chances of developing acute leukemia from long-term damage of the bone marrow. To 
overcome these challenges, combinational therapies have been used, where chemotherapy is 
used with another technique, like radiation or surgery. Another approach to the problem is the 
design of drugs that can specifically target cancer cells, as this will lower the dose of the 
chemo, thus decreasing the chances of developing acute leukemia, since they are dose 
dependent and also to reduce other side effects that are the result of the damage of DNA from 
normal cells. Chemotherapy takes many forms like immunotherapy, hormone therapy, 
radioactive materials and targeted therapy, as discussed below.  
1.4.2.2 Evolution of cancer treatments: Immunotherapy  
In the 18th century some scientists started noticing immune response to cancerous tissues. It 
was only towards the end of the 19th century that a leading New York surgeon, William B. 
Coley started to investigate this phenomenon. Coley injected streptococcal cultures into 
cancer patients and observed tumour recession. It seemed that the bacteria were triggering an 
immune response. During the following years, Coley treated many cancer patients with his 
bacterial mixture known as ‘Coley’s toxin’, with a cure rate of over 10% [15].  
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Coley’s discovery and the modern understanding of cell biology paved the way for the design 
of molecules that mimic some of the natural pathways that the body employs to regulate cell 
growth. This approach is known as biological response modifier (BRM) therapy, or simply as 
immunotherapy. 
Immunotherapy takes advantage of the body’s ability to recognise “foreign agents” known as 
antigens. Since cancer cells possess different cell-surface proteins form normal cells, the 
immune system recognises the cancer cells as different from normal body cells; therefore, 
immunotherapy uses drugs that either activates the body’s own immune system or equip the 
immune system with the necessary ”materials”, like antibodies, to fight against cancer. 
Despite the challenges involved in this approach, there has been some success. The FDA has 
approved several drugs (i.e. Rituxan and Herceptin), with many others in the clinical trials. 
Since the advancement in the knowledge of immune system in the past decades, a variety of 
immunotherapies are making their way into the clinics. They can be divided into four general 
strategies; non-specific immune stimulation, adoptive cell transfer, immune-checkpoint 
blockades and vaccinations strategies.  
The last few years have seen development of anti-cancer treatment immunotherapies, like 
growth factor inhibitors such as Iressa, Gleevec and Erbitux, together with anti-angiogenesis 
drugs like Avastin. However, there still much work to do, to help take drugs from the bench, 
through to the clinic and to the bed side. The scientists still need to find better ways to judge 
the success of immunotherapies on patients and work-out the best doses. 
1.4.2.3 Evolution of cancer treatments: Hormone therapy 
Another approach to the treatment of cancer came into existence in the 19th century, with the 
discovery made by Thomas Beatson, a graduate from the University of Edinburgh. Beatson 
experimented with rabbits and discovered that their breast stopped producing milk after the 
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removal of ovaries [5]. He further removed ovaries (oophorectomy) in rabbits with advanced 
ovarian cancer and found that oophorectomy often resulted in improvement for breast cancer 
[5]. In a nutshell, Beatson revealed the link between breast cancer and ovarian hormone 
(oestrogen), unknown in his time; this discovery spearheaded what is known today as 
hormone therapy and motivated the design of modern drugs that can treat or prevent breast 
cancer, such as tamoxifen and the aromatase inhibitors. 
Another notable contribution to hormone therapy came fifty years after Beatson’s work, by 
Charles Huggins, who demonstrated that, the removal of testicles resulted in dramatic 
recession of metastatic prostate cancer; this led to the design of drugs that inhibit male 
hormones, which were found to be effective prostate cancer treatment. Current research in 
this field has taken a new course; it’s trying to understand the influence of hormones in 
cancer development and progression. The aim is to find new ways of using drugs to lessen 
chances of developing cancer and to prevent prostate and breast cancer. 
1.4.2.4 Evolution of cancer therapy: Nuclear medicine 
The use of radioactive materials/radiotracers for medical purposes is a relatively new field, 
better known as nuclear medicine. Nuclear medicine is an essential medical specialty that 
uses radionuclides to prepare radiopharmaceuticals for diagnostic and therapeutic 
applications for some diseases, such as cancer. It began about 60 years ago and ever since it 
started, nuclear medicine has helped countless number of lives. An estimate of about 12 
million nuclear medicine imaging studies is performed every year, in the United States alone.   
Due to the multidisciplinary nature of the field; it is still not certain as to when nuclear 
medicine originated. Most scientists attribute its origins to the mid-1930s with the discovery 
of “artificial radioactivity”. Initially, radioisotopes were used for physiological 
measurements, such as blood flow measurements. The use of radioactive iodine to treat 
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patients with thyroid cancer, in 1946 marked the beginning of using radionuclides for cancer 
therapy.  
The progress in this field was sluggish, due to the shortage of radioisotopes; however, the 
development of nuclear generators in the 1960s came as a solution to the problem. The 
invention of a gamma camera in the late 1970s led to the visualization of various internal 
organs (i.e. liver, spleen, brain and gastrointestinal track) non-invasively. This led to the 
acknowledgement of nuclear medicine as an official medical specialty in 1972, by the 
American Medical Association. With the Advances in computer technology in 1980s, it was 
made possible to also use radioisotopes for diagnostic purposes. Today, nuclear medicine is a 
tremendously prized tool in the early diagnosis, prevention and treatment of several medical 
conditions. 
1.5 Radiopharmaceuticals 
In nuclear medicine, a radiopharmaceutical (RP) is either a radionuclide on its own, like 131I 
or a radionuclide that is attached to a biologically active moiety (a peptide, drug or protein) or 
a particle. A radiopharmaceutical can be introduced into the body either by injection, through 
the skin (as a cream) or can be taken orally. Once the RP is administered into the patient, it 
accumulates in the tissue or organ of interest and the imaging device, such as gamma camera 
is used to acquire a meaningful picture (Figure. 1.2).  
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Figure 1.2: Gamma ray imaging equipment [16].  
1.5.1 Considerations in the design of new radiopharmaceuticals 
When designing a radiopharmaceutical, there are various important factors that need to be 
taken into consideration. There are certain properties that a radionuclide must possess for 
optimal performance in diagnostic or therapeutic nuclear medicine. These may include the 
type of radionuclide, availability of the radionuclide, nuclear characteristics like type of 
emission, effective half-life, etc.  
1.5.2 Design of diagnostic radiopharmaceuticals 
The use of X-rays to acquire images of internal organs encouraged the naissance of other 
more sophisticated imaging modalities such as ultrasound, Magnetic Resonance Imaging 
(MRI), Computed tomography (CT), etc. These techniques provide information about the 
structural variations that transpire in the tumour growth and other different diseases that are 
imageable. Diagnostic radiopharmaceuticals provide the physicians a chance to evaluate 
physiological and anatomical processes, as well as information on various organs like 
neurodegenerative disorders, thyroid, the kidneys, Myocardial Perfusion, and others. In 
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diagnostic radiopharmaceuticals, the RP is transported to the organ of interested without 
exposing the rest of the body to radiation.  
The choice of radionuclide is very important when designing a radiopharmaceutical, as 
radionuclides have different nuclear properties, and are therefore suitable for different 
applications (e.g. as a diagnostic or therapeutic agent). In the design of diagnostic 
radiopharmaceuticals, not any gamma rays emitter is used, but only the radionuclides that 
emit γ radiation with an energy high enough to escape the body and low enough to be 
detected by the camera, that can be anything between 30 – 250 keV, but the optimum energy 
is (~ 150 keV). Table 1.1 below shows a list of commonly used radioisotopes for diagnosis 
that are considered as ideal for imaging from an energy point of view, and also includes their 
half-lives and the tissue they are used to image. The half-life of the radioisotope must be long 
enough for physiological measurements, yet short enough so as not to expose to body with 
too much radiation. 
Table 1.1: Some of the radioisotopes that are commonly used for imaging. 
Radioisotope Decay mode Half-life (h) E-max (keV) Imaging 
99mTc Isomeric transition 6,0 140 Bone, thyroid, 
brain, and kidneys 
201Tl Electron capture 73,0 135 Heart 
123I Electron capture 13,3 590 Thyroid 
67Ga Electron capture 78,2 300, 185, 93.0 Various tumours 
18F Positron emission 1,8 634 Brain 
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Depending on the type of emission, the imaging is done by Positron Emission Tomography/ 
Computed Tomography (PET/CT) or Single Photon Emission Computed Tomography 
(SPECT). The gamma and X-rays emitted by the radionuclides are detected by the SPECT 
scanners. More than 85% diagnostic scans employ 99mTc as the radioisotope for imaging. 
1.6 Technetium-99m 
Technetium is the smallest element (atomic radii) that doesn’t have a stable isotope. It was 
discovered by Perrier and Segré in 1937 [17]. Much of its chemistry was developed in 1970 
because of one of its isotopes, 99mTc. The m stands for metastable, and is used to identify an 
unstable state that exists for a finite period of time. And a nucleus in an excited state gives up 
its excess energy, and the emission occurs as γ radiation (see the equation 1). 
                           99mTc → 99Tc + γ                                                                                          (1) 
 
 99mTc possesses characteristics that are close to the ideal radionuclides for nuclear imaging 
due to its decay mechanism, but the main reason for its versatility is the availability and price 
[18]. The cost of 99mTc is very low compared with other radionuclides that might have better 
decay mechanism. Another reason is the availability of 99mTc from its 99Mo/99mTc generator. 
99mTc radioisotope is produced by the β decay of 99Mo which is loaded in aluminium column, 
and decays with the half-life of 67-h, which is continuously eluted with saline from the 
generator [18]. 99Mo is obtained through irradiation of natural molybdenum or enriched 98Mo 
with thermal neutrons in a nuclear reactor. The process is as follows: 
                         98Mo + n → 99Mo → 99mTc + β-                                                                       (2) 
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1.6.1 Tc radiopharmaceuticals 
Different technetium cores with varying oxidation states have been developed for application 
as tracers in SPECT. Some of the technetium cores that are employed include Tc-HYNIC 
core [19], fac-[Tc(H2O)3(CO)3]+, TcN3+ [20] and {TcO}3+ [21]. {TcO}3+, with Tc having the 
oxidation state of +5, is the mostly recognized and suitable for the synthesis of complexes 
that are soluble in aqueous solutions and permit variability in molecular structure and 
properties [22]. Tc radiopharmaceuticals can be broadly divided into two groups of drugs, 
namely technetium essential and technetium-tagged (99mTc targeted radiopharmaceuticals). 
1.6.1.1 Technetium essential 
Technetium essential radiopharmaceuticals are a class of molecules whose biodistribution 
depends on the presence of Tc for them to be delivered to target cells. This class includes low 
molecular weight, biologically active, technetium-ligand coordination complexes, and their 
targeting ability relies upon the size, charge, polarity and lipophilicity of the complex. 
[TcO(pnao-1-(2-nitroimidazole))] has been used as the hypoxic cell imaging agent [23], 
while the 99mTc- HEDP (1-hydroxyethylidenediphosphonate) complex has been used for 
several years to image the bone structure. Primary and metastatic lesions in the brain has been 
imaged with [99mTcO(glucoheptonate)]― [24], the structures of these complexes are shown 
below (Figure 1.3). 
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Figure 1.3: The chemical structures of (a) [TcO(pnao-1-(2-nitroimidazole))], (b) 99mTc- 
HEDP (1-hydroxyethylidenediphosphonate), and (c) [99mTcO(glucoheptonate)]―. 
1.6.2 Technetium-tagged 
Technetium-tagged radiopharmaceuticals involve labelling targeting biological active 
moieties such as antibodies, peptides, hormones with 99mTc. The targeting ability of this class 
of radiopharmaceuticals lies in the receptors that are overexpressed in cancer cells, thus this 
technique is also known as receptor-based 99mTc radiopharmaceuticals [25]. Targeted 
radiopharmaceuticals improve the tumour localizing ability of the radiopharmaceutical 
complexes used for diagnosis and radiotherapy, thus reducing side effects. Various 
monoclonal antibodies, proteins or peptides have been effectively radiolabeled and employed 
in radioimaging and targeted radiotherapy of cancer [26-29]. Technetium-tagged 
radiopharmaceuticals can be subdivided into two approaches: the integrated and the 
bifunctional approach.  
1.6.2.1 Integrated approach 
This approach includes the substitution of a part of a high-affinity receptor ligands with Tc 
without significantly alter the binding affinity, size, lipophilicity, and conformation of the 
receptor ligand [30]. Figure 1.4 is an example of integrated approach. This approach is faced 
S. Ntsimango                                                                                    Nelson Mandela Metropolitan University  
 
C h a p t e r  1   P a g e  | 17 
 
with difficulties in synthesizing the target molecule and the fact that there are significant 
structural changes (conformation and size) that lead to the loss of lipophilicity and binding 
affinity of the receptor ligands.  
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Figure 1.4: Integrated approach.   
1.6.2.2 Bifunctional approach 
In the bifunctional approach, the high-affinity receptor ligands are used as targeting 
molecules [30]. The bifunctional radiopharmaceutical is made of multiple parts, namely, the 
high-affinity receptor ligand as the targeting molecule, the bifunctional chelating agent 
(BFCA) to stabilise the metal radioisotope (Tc ions in the case of 99mTc 
radiopharmaceuticals) and to conjugate with the targeting molecule, the radionuclide for 
imaging, and sometimes the linker as the pharmacokinetic modifier [30]. The bifunctional 
approach is best represented in the analogy in Figure 1.5. 
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Figure 1.5: Analogy of targeted radioimaging and radiotherapy (lock and key mechanism) 
[31]. 
It is not surprising that this approach has had some success. There are quite a number of 
drugs that are on the market, some of these include 99mTc-d,l-HM-PAO (Ceretec®), 99mTc-l,l-
ECD (Neurolite®) or 99mTc-MAG3[32] (Figure 1.6), to image various body organs.    
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Figure 1.6: Chemical structures of some 99mTc Bifunctional radiopharmaceuticals; (a) 99mTc-
d,l-HM-PAO, (b) 99mTc-l,l-ECD and (c) 99mTc-MAG3.   
1.7 Design of therapeutic radiopharmaceuticals 
Therapeutic radiopharmaceuticals are radioactive compounds tailored to deliver therapeutic 
radiation dose to the disease sites (i.e. cancerous tumours). This technique has its advantages 
to externally applied radiation since only the organ of interest in the body will be exposed to 
the damaging radiation. Ideal radionuclides for therapeutic application emit beta particles, 
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alpha particles and Auger electrons. These particles act by posing irreparable damage on the 
nucleic DNA, which result in the inhibition of cell growth or induce apoptosis.  
Ionizing particles of medium/high energy, i.e., particles with energy above 1 MeV, are used 
in the preparation of therapeutic radiopharmaceuticals since they induce sufficient radiation 
for synchronized DNA damage. Good therapeutic results should be obtained if the half-life of 
the radionuclide is not shorter than 12 h and not longer than 5 days. The radionuclides must 
be of low cost, easily produced and be readily available in any nuclear medical facility. If the 
production of a certain radionuclide is costly, its use will be limited especially if less 
expensive alternatives are available. The therapy potential of various radionuclides has been 
studied and Table 1.2 lists a selection of potentially therapeutic radionuclides with their 
mode of decay, half-life and energy of particle type they emit.    
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Table 1.2: A selection of potentially therapeutic radionuclides. 
Radionuclide Decay mode Half-life E-maxα/β (MeV) E-maxγ (keV) 
22Bi α 60.5 min 7.8   
99mTc γ  6 h  141 
211At α 7.2 h 6.76  
186Re β 3.7 d 1.07 137 
188Re β 17 h 2.11 155 
166Ho β 1.1 d 1.6 81 
153Sm β 1.95 d 0.8 103 
109Pd β 13 h 1.10  
123I Low energy e- 13.3 h    
32P β 14.3d 1.71  
47Sc β 3.4d 0.6  
64Cu β 0.5d 0.57  
67Cu β 2.6d 0.57  
89Sr β 50.5d 1.46  
90Y β 2.7d 2.27  
105Rh β 1.5d 0.57  
111Ag β 7.5d 1.05  
117mSn β 13.6d 0.13  
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Although there are few therapeutic radiopharmaceuticals compared with diagnostic 
radiopharmaceuticals, several therapeutic radiopharmaceuticals made it to the market. FDA 
approved therapeutic radiopharmaceuticals include radium-233 dichloride (Xofigo TM) for the 
treatment of castrate-resistant metastatic prostate cancer and [33] antibody-conjugated 
actinium-225 for the treatment of acute myelogenous leukaemia [33]. 
The advent of practicable 188W/188Re generators, together with the long established 99mTc-
labelled agents and the periodic relationship of Tc and Re, provided a framework for the 
development of rhenium radiopharmaceuticals. Rhenium has two β-emitting isotopes namely, 
186Re and 188Re, which have half-lives (88.8 h and 16.9 h respectively) and energies (1.07 and 
2.11 MeV respectively) ideally suited for therapeutic treatment of cancerous tissue.  
The tissue penetration of 5 mm for 186Re makes it suitable for small tumours, whereas the 
greater 11 mm range for 188Re is more appropriate for large tumours. The half-lives are long 
enough to prolong the treatment period and the β emission energies are significantly high 
enough to deliver a radiation dose. The γ-energies are almost similar to those of 99mTc, 
therefore, the same gamma ray camera is used to monitor their biodistribution. The rhenium 
nuclides are produced as follows: 
186Re is reactor-produced via irradiation of 185Re with neutrons in a reactor  
                                         185Re + n → 186Re                                                                           (3) 
188Re can either be produced in a reactor using 187Re as a target or can be generator-produced 
from 188W/188Re generator by the following reaction: 
                                    188WO42- → 188ReO4- + β-                                                                     (4) 
188Re is acquired through the elution of the generator with 0.9% saline and obtained as 
sodium perrhenate (NaReO4).  
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1.7.1 Re radiopharmaceuticals 
Therapeutic Re radiopharmaceuticals can be designed by analogy to existing 99mTc diagnostic 
radiopharmaceuticals since the nuclides of rhenium and technetium (Group 7 congeners) 
share similar chemical behaviour, and their complexes are expected to share similar 
biodistrubution patterns. If the Re analogue is sufficiently tumour specific, then a 
therapeutically significant radiation dose can be delivered to the abnormal site without 
adversely affecting normal tissue. 
Even though the purpose for Re radiopharmaceuticals (therapeutics) and Tc 
radiopharmaceuticals (diagnostics) differs, the approach is similar.  As with technetium, 
rhenium integrated and bifunctional radiopharmaceuticals have been developed. The most 
promising results are obtained with the pentavalent chelation of rhenium, for example 188Re-
diphoshonate complexes and [ReO(DMSA)2]ˉ.  
In the bifunctional chelating approach, the chelating agent should coordinate with the 
radioisotope so as to stabilize the metal and form a thermodynamically and kinetically inert 
complex. Failure to form an inert radioactive complex between the radiometal and the 
chelating agent may lead to the dissociation of the complex once it is introduce into the 
patient as a radiopharmaceutical, which my result in an avoidable radiation in normal cells. 
The chelating agent for BFCA must have a possibility for conjugation with a targeting moiety 
and/or a linker. Phthalocyanines have proven to possess the characteristics that are close to an 
ideal chelating agent for BFCA.  
1.8 Phthalocyanines  
Phthalocyanines (Pcs) are aromatic, planar macrocycles with 18-π electron systems which are 
symmetrical and are known for their very intense green colour [34]. Pcs are closely related to 
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the naturally occurring porphyrins, where the meso methine group is replaced by aza groups, 
and the benzo groups are fused in the pyrrole rings (Figure 1.7) [35]. Due to their structure 
Pcs are very stable, both chemically and thermodynamically. Their versatile chemistry allows 
Pcs to be substituted on the peripheral (β) position or on the non-peripheral (α) position on 
the benzene ring [36]. Substitution of Pcs alters their properties, such as solubility and solves 
the problem of aggregation [37,38]. Pcs have been studied extensively and have found a 
variety of applications across a large spectrum of fields such as catalysts [39], dye-sensitized 
solar cells [40], liquid crystals [41], chemical sensors [42], photosensitizers [43], non-linear 
optics [44], semiconductors [45], photodynamic therapy of cancer (PDT) [46-47], several 
medical applications [48-50] and many other applications [51-57]. A wide variety of metals 
have been coordinated with Pcs, through the central cavity [56], and the complexes are 
known as metallophthalocyanines (MPcs).    
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Figure 1.7: Structures of phthalocyanine and porphyrin. 
Currently there is an increasing interest in the application of Pcs and MPcs for the imaging 
and therapy of cancer; most promising being photodynamic therapy (PDT) [58]. Pcs and 
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MPcs are extensively exploited in PDT because they are known to localise in cancerous 
tissues [59]. 
1.8.1 Electronic spectra of Pcs and MPcs 
Pcs and MPcs are characteristic for their intense green colour which arises as the result of the 
strong absorption band in the far red in the visible region of the spectrum, near 670 nm 
known as a Q band, usually accompanied by a vibronic shoulder. The most energetic and less 
intense band is usually observed near 340 nm and is known as a B (Soret) band (Figure 1.8) 
 
Figure 1.8: UV-Vis spectrum of a metal-free phthalocyanine. 
These observations are explained using Gourtaman’s four-orbital theory [60-62] shown in 
Scheme 1.1. This  theory suggests that these bands arise due to the electronic transitions 
between the highest unoccupied molecular orbitals (HOMO), which were calculated to be a1u 
and a2u, to the doubly degenerate eg of the lowest unoccupied molecular orbitals (LUMO). 
The Q-band is a result of the transition from a1u of HOMO to degenerate eg of LUMO. The 
broad B-band is a result of superimposition of B1 and B2 bands that arises from transitions 
between a2u and b2u of HOMO to the eg of LUMO [63]. This makes UV-Vis spectrometry a 
preferred technique for the characterization of Pcs and MPcs. A typical UV-Vis spectrum can 
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reveal whether a Pc is metalated or not, since an unmetalated Pc exhibits a split Q band, due 
to non-degenerate LUMO giving rise to two allowed electronic transitions of different 
energies (Figure 1.8).  
 
Scheme 1.1: Phthalocyanine electronic transitions. 
1.8.2 Synthesis of metallophthalocyanines 
MPcs are prepared by cyclotetramerization of various ortho-substituted benzene derivatives 
around a metals centre, which include phthalonitriles (1), phthalimide (2), phthalic anhydride 
(3), phthalic acid (4) and 1,3-diiminoisoindoline (5), to name a few or by direct metalation of 
metal-free Pc (6) (Scheme 1.2). Phthalonitriles (1) are the mostly used precursors when 
synthesizing laboratory scale Pcs due to mild reaction conditions, pure products and high 
MPcs yields obtained with phthalonitriles. 1,8-Diazabicylo-[5,4,0]-undec-7-ene (DBU) is 
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used as a catalysts for the cyclotetramerisation of phthalonitriles in solution in the presence of 
the metal centre. Direct metalation of metal-free Pcs (6) can also yield MPcs.  
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 Scheme 1.2: General synthesis of substituted MPcs with different precursors.   
1.8.3 Synthesis of substituted phthalocyanines  
Phthalocyanines can be tailored to improve their solubility and aggregation (the π-π 
interactions of Pcs lying on top of each other) through the insertion of the metal centre or by 
attaching different functional groups either in the α (non-peripheral) position or in the β 
(peripheral) position. The synthesis of ring-substituted substituted Pcs can be achieved 
through the use of precursors that have the desired substituents or through electrophilic attack 
on the benzene ring of the preformed unsubstituted Pc. The latter approach is discouraged 
due to many side reactions it produces and poor yields of the desired products.  
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Phthalocyanines can be tetrasubstituted or octasubstituted, using mono- or di- substituted 
phthalonitriles precursors. Octasubstituted Pcs tend to be less soluble as compared to 
tetrasubstituted Pcs, and this is due to the high dipole moment and the formation of 
constitutional isomers in tetrasubstituted Pcs. The use of 3- or 4-phthalonitriles to yield α and 
β substituted Pcs (respectively) results in the formation of four constitutional isomers [64]. 
Figure 1.9 depicts the constitutional isomers formed when using phthalonitriles substituted in 
position 4. The groups on these positions can be substituted or functionalised with other 
moieties to achieve the desired “complex” Pcs, through nucleophilic substitution. Pcs can be 
conjugated with biomolecules and be employed in the biological applications, to enhance 
targeting ability of the complexes.   
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Figure 1.9: Possible isomers of α-tetrasubstituted Pcs.  
1.8.4 Rhenium Phthalocyanines (RePcs) 
There are very few rhenium-phthalocyanine complexes that have been reported in the 
literature thus far [65,66]. Generally, Pcs retain a D4h symmetry owing this to their planar 
geometry. However, the RePcs possess a C4v symmetry due to the larger size of the Re(V) 
ion, which doesn’t fit in the Pcs cavity, making RePcs to have an electric dipole that is 
perpendicular to the Pc plane [67]. This has led to the formation of dimeric and sandwiched 
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RePcs complexes, but monomeric RePcs have also been reported [65-69] (see Figure 1.10). 
Göldner et al. reported the dimeric Re(II)Pcs of the type [PcRe-RePc], with a rhenium-
rhenium triple bond [67-69].  
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Figure 1.10: Re-Pc complexes; (a) Re-Re Pc complex, (b) Re-O-Re Pc dimer, and (c) 
monomeric RePcs complex.  
 
Ziener et al. reported the synthesis of [(t-Bu)4PcReO]2O; an µ-oxo dimetallate complex from 
rhenium pentachloride and 4-tert-butylphthalodinitrile [65]. The monomeric (t-
Bu)4PcReO(OEt) complex has been synthesized by the condensation of 4-tert-
butylphthalodinitrile in the presence of NH4ReO4 and a suitable reducing agent [65]. Ziener 
et al. also reported the synthesis of unsubstituted RePc from NH4ReO4 phthalodinitrile to 
form PcReN [65]. The most recent synthesis of monomeric RePcs is achieved with the amido 
group attached to the metal centre and occupying the axial position, with the macrocycle in 
the equatorial position [66].  
The scarcity of the literature on the synthesis of monomeric ReOPc displays the need to 
further explore the coordination of Pcs to Re, more especially oxo rhenium(V) for biological 
applications, since Re with the oxidation state of +5 complexes were shown to be soluble and 
stable under physiological conditions [22]. The direct synthesis of preformed, metal-free 
phthalocyanines, has also not been reported in the literature. The incorporation of rhenium to 
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the phthalocyanine macrocycle would be novel synthesis that could not be achieved with 
porphyrin. The exploitation of the tumour-localizing ability of biomolecule-conjugated 
metallophthalocyanines would open up a new class of radiopharmaceuticals. 
1.9 Nanotechnology 
Having witnessed the advances and successes in the field of nanotechnology, scientists across 
various disciplines applied nanotechnology as another approach to address the issue of 
cancer. Nanotechnology is the “work horse” of nanoscience, in the sense that it focuses on 
discovering novel behaviours and properties of materials with dimensions on the nanoscale, 
which varies roughly between 1 and 100 nm.  Nanotechnology is the application of the 
discoveries made in nanoscience. In other words, nanotechnology is the art of building and 
using materials, devices, and machines at the nanometer scale. “Nano” is a Greek word for 
“dwarf”, means (10-9), or one-billionth. In the case of nanotechnology, it means one-billionth 
of a meter or 1 nanometre (nm).  To put the nanosize into context, 1 nanometre is equivalent 
to 3 atoms long. At this size, materials work differently and present amazing and very 
interesting properties (e.g. lower melting points, higher surface areas, mechanical strengths, 
etc.). For this reason, nanomaterials have attracted a significant interest and have been 
employed for various applications. Table 1.3 summarises the applications of nanomaterials in 
fields. Nanoparticles (NPs) have also made their way into every branch of medicine [70-75]. 
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Table 1.3: Applications of nanomaterials in different fields [76]. 
Applied field Applications 
Materials  Nanoparticles, carbon nanotubes, biopolymers, paints, 
coatings 
Chemistry Catalysts  
Environment and energy Water and air purification filters, fuel cells, photovoltaic 
Food science  Processing, nutracetical food, nanocapsules 
Chemical and cosmetics Nanoscale chemicals and compounds, paints, coatings  
Nanomedicines and pharmacuetics Nano drugs, medical devices, tissue engineering, molecular 
imaging, therapeutics, pesticides  
Electronics  Biosensors, sensory enhancement, semiconductor chips, 
memory storage, photonica, optoelectronics  
 
1.9.1 Nanoparticles in medicine 
Recently, there has been an exponential growth in the use of nanoparticles in the biomedical 
research [77]. The use of nanoparticles in medicine (nanomedicine) will radically change the 
way we approach diagnosis and therapy of diseases states such as cancer, since they possess 
the ability to overcome the shortcomings that are presented by traditional drugs i.e. drug 
resistance at the tumour level due to physiological barriers, drug resistance at the cellular 
level, distribution, biotransformation and clearance of anticancer drugs in the body [78].  
Nanoparticles have a surface that is easily modified, small size, large surface area to volume 
ratio, high reactivity to the living cells, stability over high temperatures and translocation into 
the cells [79]. NPs also display unique optical properties, making them capable of producing 
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quantum effects suitable for imaging applications [77,80,81]. They can be used in medicine 
to serve as dual detection devices for both magnetic resonance and fluorescent microscopy 
(Figure 1.11) [81]. Nanoparticles of size <50 nm can easily accumulate inside the cells, 
while the ones with diameter <20 nm can exit blood vessels, making them suitable candidate 
to interact with biomolecules on the cell surface and within the cells [81].  
 
Figure 1.11: Medical applications of nanoparticles: (A) in vitro labelling of cancer cells by 
CdS/ZnS core-shell quantum dots, and (B) non-invasive imaging of live rat with quantum 
dot-encoded multicolour bead [82].  
1.9.1.1 Nanoparticle-based targeting  
Nanoparticles are extensively explored as potential drug delivery systems that can deliver 
chemotherapy drugs, light, heat, radioactive and other substances specifically to cancer cells. 
With the advancement in the knowledge of cellular biology, scientists have discovered and 
identified receptor that bind specific biomolecules that are overexpressed in cancer cells and 
down regulated in normal cells. With this understanding, NPs are engineered to recognise and 
precisely bind to diseased cells, through the use of targeting moieties such as biological 
active molecules, and sometimes synthetic biomimic compounds.  
The targeting approach is based on interactions such as lectin-carbohydrate, ligand-receptor, 
and antibody-antigen [82]. Targeting enables clinicians greatly reduce side effects that are 
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associated with damage of healthy cells with toxic substance that are used to treat cancer and 
overcome the multiple drug resistance (MDR) issues. MDR is as a result of overexpression of 
P-glycoprotein (Pgp) on the plasma membrane of cancer cells [83]. Pgps act by excluding 
positively charged xenobiotics out of the cells, together with many anti-cancer drugs through 
the efflux pump mechanism. Pgps are known to be incapable to eradicate polymer-drug 
conjugates (nanospheres) that enter the cell through endocytosis; this makes targeted 
nanomedicine a valuable tool to overcome MDR [84]. Targeted NPs has been successfully 
developed and are in different phases of clinical trials and their approval for use in cancer 
patients is pending [85].  
1.9.1.2 Nanoradiopharmaceuticals 
The application of nanotechnology in medicine has also been extended to 
radiopharmaceuticals. In this direction a novel and promising science called 
nanoradiopharmaceuticals (NRPs) developed. Nanoradiopharmaceuticals are radiolabelled 
nanomaterials designed to deliver therapeutic doses of ionizing radiation to specific 
cancerous foci sites with high specificity in the body. They have already made their way to 
clinical investigation for use in physiological systems [86]. There two possible approaches 
that are used to synthesize nanoradiopharmaceuticals.  
They can be prepared through direct nanoencapsulation of radioactive radiopharmaceuticals 
(Figure 1.12a). For example, Trau et al. reported the synthesis of nanoencapsulated 
microcrystalline nanoparticles for superamplified biochemical assays [87]. The radiolabeled 
molecules were encapsulated within ultrathin polyelectrolyte layers of poly(allylamine 
hydrochloride) and poly(sodium 4-styrenesulfonate) that are functionalised with targeting 
molecules and are released in the tumour site [87].    
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Figure 1.12: The nanoradiopharmaceutical approaches: (a) direct   nanoencapsulation of 
radioactive radiopharmaceuticals [88], and (b) radiolabeled nanoparticle [89]. 
The second approach involves direct radiolabeling of NPs coated with non-radioactive ligand 
by a radioisotope (Figure 1.12b). NPs have been successfully radiolabeled with both α-
emitters (e.g. 211At and 225Ac) and β-emitters like (e.g. 90Y, 67Cu, 131I, 186Re, and 188Re) [90]. 
For example, Hong et al. reported the synthesis of radiolabeled iron oxide nanoparticles 
which have been designed for use in SPECT/MRI and PET/MRI dual techniques [90]. Both 
these approaches yield the nanoradiopharmaceuticals. 
Even though molecular imaging techniques have advanced, there is no single technique that 
is perfect and adequate to acquire all the required information for a specific question [91]. For 
example, there are drawbacks associated with quantifying fluorescence signals in biological 
systems, specifically in deep tissues; MRI has very high resolution but it have low sensitivity; 
Radionuclide-based imaging methods possess high sensitivity yet they suffer for poor 
resolution [90]. Combination of various molecular imaging techniques can be advantageous 
compared to a single technique. Rhenium stands as a good candidate for 
nanoradiopharmaceuticals because of its good nuclear properties, physical half-life, and 
decay characteristics.  
 
(a) (b) 
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1.9.2 Preparation of nanoparticles 
Nanoparticles synthesis can be achieved using materials of various chemical nature, with 
biomolecules, carbon, metals, metal oxide, non-oxide ceramics, organics, polymers and 
silicates being the most used. Nanoparticles exist in a number of different morphologies such 
as spheres, cylinders, platelets, tubes, etc. Nanoparticles are generally designed in such a way 
that their surfaces can be modified to meet the needs of specific applications that they are 
synthesized to be used for. The enormous diversity of the nanoparticles (Figure 1.13), arising 
from their wide chemical nature, shape and morphologies, the medium in which the particles 
are present, the state of dispersion of the particles and most importantly, the numerous 
possible surface modifications the nanoparticles can be subjected to make this an important 
active field of science now-a-days. Nanoparticles can be synthesized by one of the two 
approaches; bottom-up or top-down approach. 
 
Figure 1.13: Various features contributing to the diversity of engineered nanoparticles [92]. 
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1.9.2.1 Top-down/physical approach 
The top-down approach involves modifying large objects in order to create smaller objects 
with desired size and shape, and improved features. This approach uses techniques like 
lithography and mechanical techniques (e.g. machining, polishing and grinding) [93]. The 
nanoparticles produced by this method become reactive after they are processed and they 
possess a high surface energy which is decreased by adsorption or agglomeration of a certain 
species, hence some additional reaction occurs. During the synthesis of nanoparticles specific 
materials are being used up in order to coat and this controls a further interaction with other 
particles. Top-down techniques are more frequently accomplished on the industrial scale 
[94]. 
1.9.2.2 Bottom-up/chemical approach 
This method involves the use of small building blocks that are assembled to prepare a large 
structure such as the chemical reduction of metal ions [95], forming stable nuclei and 
ultimately the growth of the NPs. The mostly used reducing agents in the synthesis of 
metallic nanoparticles are ascorbate, sodium citrate, ethylene glycol and sodium borohydride 
(NaBH4). NPs produced in this way tend to bind to agglomerate and form larger aggregates 
[96] due to the large surface area of the nanoparticles, which intensifies their van der Waals 
interactions. To overcome agglomeration of NPs, capping agents such as alcohols, acids, 
thiols and amines have been employed so as to stabilize the NPs.  
The advantages of using Bottom-up approach include the ability of facile fabrication of NPs 
of different shapes and the possibility to fine-tune the shape and size of NPs, by changing the 
amounts of the reducing agent and the metal salt, temperature, reaction time, and the amount 
of the capping agent. A variety of metal and metal oxide nanoparticles have been synthesised 
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with this method with great success. The most commonly studied metal nanoparticles for 
medical applications include gold, silver, titanium oxide and iron nanoparticles [77,97]. 
However, the synthesis and characterization of group 7 transition metal nanoparticles have 
been reported in very few articles [98].   
1.9.3 Characterization of nanoparticles 
The characterization of nanoparticles is generally carried out using advanced microscopic 
techniques such as scanning electron microscope (SEM), transmission electron microscopy 
(TEM), X-ray photoelectron spectroscopy (XPS) and atomic force microscopy (AFM). With 
these previously mentioned techniques, the size, morphology and surface charge can be 
determined; these physical properties can affect the physical stability and the in vivo 
distribution of the nanoparticles [99].   
1.9.4 Rhenium nanoparticles 
Despite the plethora of literature on the synthesis of metal oxide nanoparticles, little is known 
about rhenium oxide nanoparticles. Re2O7 based nanostructures that are immobilized within 
Al2O3 and SiO2 have been synthesized for catalytic purposes [100].  Pawlak et al. reported on 
the synthesis of Re2S7 nanostructures, which have the potential to be applied in nuclear 
medicine [101]. Most of the literature reports the synthesis of Re nanoparticles from various 
precursors, using different approaches that are not sodium borohydride reduction [102,103], 
but however, the synthesis of Rhenium Oxide nanoparticles from perrhanate (ReO4-) ion 
using sodium borohydride as the reducing agent has been reported by [104] for catalytic 
applications.  
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1.10 Scope of the study  
The goal of this study is the development of rhenium-phthalocyanine complexes and 
nanoparticles-based radiopharmaceuticals for therapeutic and diagnostic applications. The 
objectives of the study are listed below:  
• Synthesis and characterization of metal-free tetra-substituted phthalocyanines and 
folate conjugated-phthalocyanines.  
• Direct metalation of metal-free phthalocyanines with rhenium in its perrhenate form 
to yield Re(V)-phthalocyanine complex.  
• Synthesis, optimization and characterization of folic acid conjugated phthalocyanine- 
capped rhenium(III) oxide  nanoparticles.  
• In vitro studies towards localization of rhenium nanoparticles on cancer cell lines.   
S. Ntsimango                                                                                    Nelson Mandela Metropolitan University  
 
C h a p t e r  2   P a g e  | 38 
 
Chapter 2 
….. 
Materials, experimental methods and techniques 
2.1 General reagents  
Table 2.1 General reagents used in this study 
Chemical name %Purity or 
concentration 
Supplier 
Acetic acid  Glacial  Sigma-Aldrich 
ammonium perrhenate 99 Sigma-Aldrich 
1,8-diazabicyclo[5.4.0]undec-7-ene 98 Sigma-Aldrich 
Diethylether 99 Merck Chemicals 
Dimethyl sulfoxide 99 Merck Chemicals 
Ethanol Analytical grade Merck Chemicals 
Ethyl acetate 98.8 Sigma-Aldrich 
Folic acid 97 Sigma-Aldrich 
Hexane 97 Merck Chemicals 
Hydrochloric acid 32 Sigma-Aldrich 
Methanol Analytical grade Merck Chemicals 
N-Hydroxysuccinimide 98 Sigma-Aldrich 
N,N’-Dicyclohexylcarbodiimide 99 Fluka 
N,N’-Dimethylformamide 99.8 Sigma-Aldrich 
4-Nitrophthalonitrile 99 Fluorochem 
n-Octanol 99 Sigma-A;drich 
Pyridine 90 Merch Chemicals 
Pyridine-HCl 98 Alfa Aesar 
Sodium acetate 99 ACE Chemicals 
Sodium borohydride 98 Sigma-Aldrich 
Sodium chloride 99.5 ACE Chemicals 
Sodium metabisulphite 98 ACE Chemicals 
Sodium sulphide nonahydrate 98 Sigma-Aldrich 
Triphenylphosphine 99 Merck Chemicals 
Toluene 99 ACE Chemicals 
Zinc(II) chloride 98 Merck Chemicals 
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2.2 Equipment  
2.2.1 Spectroscopic techniques 
2.2.1.1 Nuclear magnetic resonance (NMR) spectroscopy  
The structures of the hydrolysis products were determined by using 1H NMR and 13C NMR 
spectroscopy on a Bruker AMX 400 NMR MHz spectrometer and reported relative to 
tetramethylsilane (δ 0.00). 
2.2.1.2 Infrared Spectroscopy 
The infrared spectra were recorded on a Bruker, Tensor 27 platinum ATR-FTIR 
spectrophotometer in the range 4000−400 cm−1. 
2.2.1.3 UV-Vis Electronic Spectroscopy 
The absorption spectra of the phthalocyanine derivatives and the hydrolysis products were 
recorded on a Thermo Scientific UV-Vis spectrophotometer using 1 cm quartz cells. The 
spectra were recorded in the wavelength range of 300-900 nm, using DMSO as a solvent. 
Absorption spectra of rhenium nanoparticles were also recorded with same specifications. 
2.2.1.4 Magnetic circular dichroism (MCD) 
Magnetic circular dichroism (MCD) spectra were measured on a Chirascan Plus 
spectropolarimeter equipped with a permanent magnet, which produces a magnetic field of 1 
T (1 tesla) [64]. 
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2.2.1.5 Time correlated single photon counting (TCSPC) 
Excitation and emission were measured with a FluoTime 300 EasyTau spectrometer 
(PicoQuant GmbH) using a time correlated single photon counting (TCSPC). A diode laser 
(LDH-P-670, 20 MHz repetition rate, 44 ps pulse width, Pico-Quant GmbH) was employed 
to excite the samples at 670 nm. The detector used was a Peltier cooled photomultiplier 
(PMA-C 192-M, PicoQuant GmbH). 
2.2.2 Microscopic techniques 
2.2.2.1 Transmission Electron Microscopy (TEM) 
TEM images of the rhenium nanoparticles and HCC1806 were acquired with a Zeiss Libra 
120 transmission electron microscope equipped with an EDAX detector and Gatan 
Crystorage. To prepare the samples, few drops of the nanoparticle suspension were placed on 
a 3-mm carbon-coated copper grid. The copper grids were covered with petri dish and were 
left to dry at room temperature overnight. The images were captured using the embedded 
self-imaging system using a Megaview III digital camera.  
2.2.2.2 Confocal microscope 
Confocal fluorescence images were captured with Zeiss LSM 510 Meta laser scanning 
confocal microscope and analysed using Zen software (blue edition, Zeiss, Germany) or 
AxiovisionLE 1.4.7 (Carl Zeiss Imaging Solutions Germany). 
2.2.2.3 Ultra-microtome 
Thin sectioning of the Re NP impregnated cells was achieved with PowerTome XL ultra-
microtome, and a special diamond knife.    
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2.2.3 Other Instruments 
2.2.3.1 Melting points 
The melting points of the solid complexes were determined with the electrothermal IA 9000 
digital measuring point apparatus. 
2.2.3.2 Centrifuge  
Labofuse 200 Heraeus sepatech centrifuge was extensively used for phthalocyanine 
purification and in cell line preparations. 
2.3 Preparative aspects  
2.3.1 Synthesis of TAPc and TNPc 
Tetraamino-phthalocynine (TAPc) was synthesized by using a method reported in the 
literature [105]. Synthesis of TAPc was accomplished in three steps: (i) synthesis of 
tetranitro-zinc-phthalocyanine (TNZnPc), (ii) reduction of tetranitro-zinc-phthalocyanine to 
tetraamino-zinc-phthalocyanine (TAZnPc); and (iii) removal of zinc(II) to form tetraamino-
phthalocyanine (Scheme 2.1).   
2.3.1.1 Tetranitro-zinc-phthalocyanine (TNZnPc)  
The synthesis of TNZnPc was based on a literature method [105]. 4-Nitrophthalonitrile (5.14 
g, 29.7 mmol) and zinc chloride (1.23 g, 7.42 mmol) were added into n-octanol (8 ml), and 
catalytic amounts of 1,8-diazabicyclo[5.4.0]undec-7-ene was added into the reaction mixture. 
The reaction was allowed to proceed at 180ºC for 4 h. Thereafter, the reaction mixture was 
cooled and diluted with toluene (80 ml), and the precipitate that resulted was collected by 
centrifugation at 6400 rpm for 30 min. The solid was filtered and washed with toluene, water, 
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MeOH/ether (1:9), and then EtOAc/hexane (2:1). The dark green solid that resulted was dried 
and weighed (5.08 g, 92%). 
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Scheme 2.1: The synthesis of tetranitro-zinc-phthalocyanine from 4-phthalonitrile. 
2.3.1.2 Tetraamino-zinc-phthalocyanine (TAZnPc)  
TAZnPc was synthesized under a nitrogen atmosphere at 65ºC by dissolving  4.08 g (5.35 
mmol) of TNZnPc in 80 ml DMF, followed by addition of 15.88 g (66.1 mmol) of sodium 
sulfide nonahydrate. The reaction mixture was allowed to continue overnight, and then 
cooled to room temperature (Scheme 2.2). It was then diluted with cold water (200 ml) and 
the resulting precipitate was collected by centrifugation at 6400 rpm for 30 min. The 
precipitate was repeatedly washed with MeOH/ether (1:9), EtOAc and dried to afford a dark 
green solid (2.46 g, 72%).  
2.3.1.3 Tetraamino-phthalocyanine 
TAZnPc was demetalated by dissolving 1.5 g in a solution of pyridine (4 ml) and 
pyridine•HCl (2 g) while being stirred, under nitrogen, at 110ºC for 17 h. The reaction was 
stopped and 20 ml of H2O was used to cool the mixture. Centrifugation was used to collect 
the dark green precipitate at 6400 rpm for 30 min, followed by filtration and washing 
repeatedly with H2O, MeOH and EtOAc. The product (TAPc) was dried under vacuum and a 
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yield of 93% was obtained. TNZnPc was also demetallated in a similar manner as TAZnPc to 
form TNPc with a yield of 85%.    
2.3.1.4 Synthesis of tetraamino-phthalocyanine (TNPc) 
The synthesis of TNPc was achieved by dissolving TNZnPc (0.65 g) in a mixture of pyridine 
(2 ml) and pyridine•HCl (1 g) while being stirred, under nitrogen, at 110ºC for 18 h. After the 
reaction run to completion, 10 ml of ice cold H2O was poured in the mixture. Centrifugation 
was used to collect the dark green precipitate at 6400 rpm for 30 min, followed by filtration 
and washing repeatedly with H2O, MeOH and EtOAc. The product was dried under vacuum 
and a yield of 85% was obtained.    
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Scheme 2.2: Synthesis of tetraamino-phthalocyanine (TAPc) and tetranitro-phthalocyanine 
(TNPc). 
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2.3.2 Rhenium(V) mediated oxidative hydrolysis of Pcs 
2.3.2.1 Oxidative hydrolysis of TNPc 
To a DCM solution (5 mL) containing 1 g of tetranitro-phthalocyanine (TNPc) and 0.42 g of 
NH4ReO4, a solution of triphenylphosphine (0.02 g in 2 mL H2O) was added and the mixture 
was heated at 190ºC for 4 h (Scheme 2.3). The reaction mixture turned from a dark green 
colour, which is characteristic of Pcs, to a yellow colour. The solution was analysed using 
UV-Vis spectrophotometry and GC-MS. Single crystals also formed from this solution after 
three weeks of standing at room temperature, and these were analysed using single crystal X-
ray diffraction (SCXRD). In the hydrolysis of TNPc the results were; Yield = 64%, Mp = 
142°C. 1H NMR (ppm): 8.45 (d, C(15)–H), 8.67 (d, C(16)–H), and 9.03 (s, C(12)–H). 13C 
NMR (ppm): 115.38 (C(1)–N(2), 115.07 (C(2)–N(3)), 150.25 (C(11)–(N(1)), 117.10 C(13)), 
120.72 C(14)), 129.33 C(12), 129.02 C(16)), 136.15 (C(15) (see the crystal structure for the 
numbering). IR (ν max, cm−1): 3102 and 3049 (aliphatic C–H), 2240 (C N), 1536 (N–O, 
asymmetric), 1353 (N–O, symmetric), 1608 and 1586 (aromatic C=C), 1300 (C–N). GC-MS 
(m/z) M+: Found for C8H3N3O2 = 173.0, Calculated mass = 173.13.   
NH
N
N
N
N
HN
N
N
R R
RR
CN
CN
R
NH4ReO4, PPh3
n-Octanol and H2O
R = NO2 or NH2
 
Scheme 2.3: General reaction scheme of the hydrolysis of Pc. 
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2.3.2.2 Oxidative hydrolysis of TAPc 
The hydrolysis of TAPc was carried out in the same manner as described for TNPc 
hydrolysis, and the following results were obtained. Yield = 58%, Mp = 180°C. 1H NMR 
(ppm): 7.89 (s, 1H), 7.63 (d, 1H), 7.57 (d, 1H) and 3.43 (d, 2H).13C NMR (ppm): 129.28 
(C(1)–N(2), 129.17 (C(2)–N(3)), 133.73 (C(11)–(N(1)), 131.90 C(13)), 132.00 C(14)), 
132.59 C(12), 132.48 C(16)), 132.71 (C(15). IR (ν max, cm−1): 2965 and 2923 (N–H), 2851 
(shoulder band), 2255 (C N), 1718 (N–H), 1262 (C–N), 721 (N–H). GC-MS (m/z) 
[M+H]+: Found for C8H5N3 = 144.0, Calculated mass = 143.03. 
2.3.3 Conjugation of TAPc with folate 
The synthesis of folate conjugated tetraamino-phthalocyanine was achieved according to 
literature [106] with minor adjustments as follows; 100 mg of Folic acid was added to the 
mixture of H2O and DMSO (1:9) and was stirred along with 70 mg DCC and 39 mg NHS for 
24 h. Then the solution of TAPc (233 mg) in DMSO was added and the solution was further 
stirred at room temperature for 48 h (Scheme 2.4). The solid product was acquired through 
centrifugation of the resulting solution at 7000 rpm for 10 min. The yield was 61%. IR (cm-1): 
3336 (N-H), 2935, 2853 (C=C) and 1694 (C=O). UV-Vis (nm): 740, 358 and 298. MCD 
(nm): 664 and 763. LC-MS (m/z) [M+2H]+: Found for C8H5N3 = 1017.82, expected mass 
[M]+ = 1015.21. 
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Scheme 2.4: Conjugation of tetraamino-phthalocyanine (TAPc) with folate (FA). 
2.3.4 Direct metalation of metal-free Pcs with rhenium 
100 mg tetraamino-phthalocyanine and 80 µL of 1M HCl were added in 4:1 n-Octanol/H2O 
and stirred at 190oC for 3 min. Subsequently 5 mg of ammonium perrhenate and 50 mg 
sodium metabisulphite were added and the reaction mixture was allowed to continue for 4 h 
(see Scheme 2.5). Thereafter, the reaction mixture was cooled to room temperature and 
diluted with ethanol (20 ml), and the precipitate that resulted was collected by centrifugation 
6400 rpm for 30 min. The solid was filtered and washed with water, MeOH/ether (1:9), and 
then EtOAc/hexane (2:1). The yield was 20%. IR (cm-1): 3381, 3245, 1612 (N-H). UV-Vis 
(nm): 694 and 318. MCD (nm): 720, 667, 376, 335 and 358.  
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Scheme 2.5: Direct synthesis of rhenium(V)-phthalocyanine (Re-Pc) complex from 
tetraamino-phthalocyanine (TAPc). 
2.3.5 Synthesis of rhenium nanoparticles 
The synthesis of Re NPs followed a procedure reported in [107] with some modifications. In 
a typical synthesis of phthalocyanine capped rhenium nanoparticles, 80 µL of an aqueous 
solution of ammonium perrhenate (100 mM), 2000 µL acetate buffer and 450 µL deionized 
water were mixed and were left to stir under nitrogen for 30 min at room temperature. After 
the 30 min was over, 400 µL of freshly prepared solution of NaBH4 was added dropwise to 
the reaction mixture over a period of 1 min, during which the solution turned from colourless 
to tan. 1 min after the addition of NaBH4, FA-TAPc solution in DMSO (10 mg/ml) was 
added slowly. The solution was further stirred for another 30 min under nitrogen and 
vigorous agitation. The solution was transferred to polyethylene tubes and was subjected to 
centrifugation, followed by filtration. The NPs remained in solution and to prepare the NPs 
for TEM analysis. The images were taken from random chosen areas and ImageJ software 
was used to calculate nanoparticle size distribution.  
2.3.6 Cell lines and culture conditions 
The breast cancer cell lines, MDA-MB-231, HCC70, HCC1806 that show, low, medium and 
high amounts (respectively) for receptors that are overexpressed for folate, were retained in 
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Dulbecco’s Modified Eagle Medium (DMEM) culture supplemented with 5% (v/v) heat-
inactivated FCS, 1 mM Lglutamine, 100 U/ml penicillin and 100 μg/ml streptomycin 
(Pen/Strep) at 37°C in a humidified 9% CO2 incubator, as described in [108]. The 
immortalized non-cancerous HEK cells were maintained using a 1:1 ratio of Ham’s F10 and 
DMEM supplemented with 5% (v/v) heat inactivated FCS, 100 U/ml penicillin and 100 
μg/ml streptomycin (Pen/Strep), 20 ng/ml EGF, 100 ng/ml cholera toxin, 500 ng/ml 
hydrocortisone and 10 μg/ml insulin. 
2.3.7 Cell proliferation assay 
The elucidation of cell viability studies of the cell lines treated with the nanoparticles were 
evaluated with the aid of the MTT assay according to manufacturer’s instructions. In short, 
the cells were seeded at 6,000 cells per well in a 96-well plate and allowed to settle overnight. 
Consequently,  the cells were treated with a range of concentrations (0,0.5,5,50,250 and 500 
µM) of the two different particle sizes of  FA-PATc capped Re NPs, FA or methanol 
(MeOH) vehicle control (0.02 % v/v MeOH) for 96 hours and absorbance at 595 nm recorded 
using a Powerwave spectrophotometer (BioTek). The same procedure was also followed for 
50 nm Re NPs capped with TAPc for comparison purposes. To avoid confusion, the NPs that 
are capped with an unconjugated TAPc will be referred to as bare NPs. The half maximal 
inhibitory concentration (IC50) for each compound was calculated relative to the vehicle-
treated control from a dose response curve (log concentration vs absorbance at 595 nm) using 
non-linear regression with GraphPad Prism 4 (GraphPad Inc.). 
Paclitaxel (PTX) was included as a positive control (IC50 of 100 nM). All treatments were 
conducted in triplicate on each of the two plates. 
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2.3.8 Cytotoxicity detection by flow cytometry 
The cytotoxicity response induced by the nanoparticles on the cell lines was calculated by 
flow cytometry with Hoescht 33342 nuclear staining. Cells of MDA-MB-231, HCC7, 
HCC1806 and HEK were seeded (5×105) in 75 cm2 flasks and permitted to settle and grow 
over 24 h afore treating with the appropriate compounds overnight. The cells were treated 
with trypsin and carefully lifted, subsequently; the cells were subjected to washing and 
resuspension in pre-warmed bovine serum albumin (BSA) (2% in phosphate buffered saline). 
Hoescht 33342 was added to the untreated cells 1 μg/ml concentration and the mixture was 
vortexed and incubated at 37°C for 7 min. An additional 1 μg/ml concentration of Propidium 
iodide (PI) was added to the cells and incubated on ice for 10 min and analysed on a FACS 
Aria II flow cytometer using FACS Diva software. Ultraviolet laser was used to excite 
Hoescht 33342 at 355 nm and emission was detection was done in the 450/50 channel, 
whereas blue laser was used to excite PI at 488 nm and the detection was done in the 610/20 
channel. Data analysis was done using FlowJo software Version 7.6.1. (TreeStar Inc., 2010). 
2.3.9 Cells-uptake studies: Confocal fluorescence microscopy 
The cell-uptake studies were also carried-out on the HCC1806 (the cells that shown highest 
folate overexpression), to verify the cell localising ability of the nanoparticle systems. 
HCC1806 cells were seeded (5×105) in 75 cm2 flasks and permitted to settle and grow over 
24 h before treating with 0.5 µM FA-TAPc capped Re NPs (sizes 10 nm and 50 nm) and 
uncapped Re NPs (50 nm), FA, MeOH and Hoescht 33342 overnight. Afterwards, the cells 
were treated with trypsin and carefully lifted. Subsequently; the cells were subjected to 
washing and resuspension in pre-warmed bovine serum albumin (BSA) (2% in phosphate 
buffered saline). Zeiss LSM 510 Meta laser scanning confocal microscope was used to 
capture the pictures of the cells containing the relevant compounds, that were excited at 350 
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nm and emission was detection was done in the 450/50 channel. The results obtained were 
analyzed using Zen software (blue edition, Zeiss, Germany) or AxiovisionLE 1.4.7 (Carl 
Zeiss Imaging Solutions Germany). 
2.3.10 Cells-uptake studies: Transmission electron microscope 
To verify the results obtained with confocal fluorescence microscope, the transmission 
electron microscope was employed. The same procedure in section 2.3.9 was followed. That 
is, the cells were seeded, grown and treated with the Re NPs. Afterwards; the cells were 
treated with trypsin and carefully lifted and placed inside centrifuge micro tubes. Preparations 
of the cells for viewing under TEM was done as detailed below: 
Primary fixing: 2.5 M glutaraldehyde was added on the cells and refrigerated at 5°C for 60 h. 
After the 60 h has lapsed, the cells were subjected to washing with 0.1 M sodium phosphate 
buffer two times for 10 min. 
Secondary fixing: Osmium tetroxide was added on the cells and waited for 90 min at room 
temperature. After the 90 min, the cells were washed with 0.1 M sodium phosphate buffer 
two times for 10 min (see Table 2.2).  
Dehydration: Subsequently, the cells were subjected to a serious of washing with different 
solvents. Table 2.3 lists the solvents that were used and times.  
Cell embedment: Afterwards, the cells were suspended in a pure resin for 720 min, pure resin 
was added again into the cells and the cells were placed in an oven at 600C for 36 h. After 36 
h came to an end, the resin had solidified. 
Thin cell sectioning: The solidified risen that contains the cells was fashioned in to pellets 
and ultra-microtome was used to section the cells (embedded inside the pellets) into the 
thickness of 80 nm, at the cutting speed of 0.7 mm/sec, using a diamond knife. 
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Table 2.2: Primary and secondary fixation of the cells. 
Task Substance Time (min) 
Primary fixation 2.5 M Glutaraldehyde 1200  
Washing (x 2) 0.1 Sodium phosphate 10 
Secondary fixation Osmium tetroxide 90 
Washing (x 2) 0.1 Sodium phosphate 10 
 
Table 2.3: Solvents that were used to wash the cells after fixation.  
Solvent Time (min) 
30% ethanol 5 
50% ethanol 5 
70% ethanol 5 
80% ethanol 5 
90% ethanol 5 
Absolute ethanol 5 
Absolute ethanol 5 
Propylene oxide 15 
Propylene oxide 15 
75/25 Pro-resin 60 
50/50 Pro-resin 60 
25/75 Pro-resin 60 
Pure resin 720 
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Chapter 3 
..... 
Results and discussion  
 
3.1 General introduction 
There has been a significant interest in rhenium coordination chemistry due to the interesting 
nuclear characteristics that are shown by its radioisotopes (186/188Re) which are desirable for 
therapeutic and diagnostic applications [23]. The main focus is on +5 oxidation state since it 
can easily be obtained from the reduction of Re(VII) and can easily be coordinated with a 
variety of ligands to form stable complexes [109]. Oxygen- and nitrogen-containing rhenium 
complexes dominate the chemistry of the Re(V) oxidation state. Such complexes show 
multiple bonds between rhenium and donor ligands, e.g. [Re=O]3+, [Re N]2+, [Re=NR]3+ or 
[Re=S]3+. This arises due to the ability of π donating O2- and N3- to neutralise the high formal 
charge on the metal centre, leading to the formation of very stable diamagnetic Re(V) 
complexes [109]. In some complexes, the oxo group occupies the axial position, while four 
ligands reside in the equatorial position. In some cases, a ligand can be weakly bound trans to 
the oxo group [110]. A similar chemistry has been observed with rhenium(V)-phthalocyanine 
complexes, e.g. PcReN, (t-Bu)PcReN and [PcRe(NR)Cl], where the imido and chloride 
ligands reside in trans axial positions (Figure 1.10).      
This chapter details the attempts made on the syntheses of oxo rhenium(V)-phthalocyanines 
via direct reductive metalation of metal-free phthalocyanines with rhenium in its perrhenate 
form.  Radioactive rhenium is generator-produced from a 188W/188Re generator and is 
acquired through the elution of the generator with 0.9% saline and obtained as sodium 
perrhenate (NaReO4). Most of oxo rhenium(V) complexes are prepared by first converting 
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NaReO4 to other precursors such as [ReOCl3(PPh3)2] [111], [ReO2I(PPh3)2] [112], and NH4 
[ReOCl4] [113], to name a few.  
In this study, rhenium was used directly in its perrhenate form, so as to minimise reaction 
steps because fewer steps are required when synthesizing radiopharmaceuticals. To 
synthesize rhenium(V)-phthalocyanine complexes, three different two-electron reducing 
agents (triphenylphosphine (PPh3), sodium metabisulphite (Na2S2O5) and sodium 
borohydride (NaBH4)) were used to reduce rhenium(VII) to rhenium(V). Subsequently very 
different results were obtained such as the rhenium(V)-mediated oxidative hydrolysis of the 
Pcs to phthalonitriles, Re(V)-Pc complex and rhenium nanoparticles (Re NPs). These 
observations are discussed in the following sections.    
3.2 Rhenium(V)-mediated oxidative hydrolysis of Pcs  
The phthalocyanines were prepared via tetracyclomerization of 4-nitrophthalonitrile around 
zinc(II) to form TNZnPc. The reduction of the nitro substituents on TNZnPc was carried out 
to form TAZnPc followed by the extrication of the central zinc ion to form metal-free Pc 
(TAPc). This synthetic route was chosen instead of a one-step synthesis of metal-free Pcs 
[105] because of the higher yields that could be achieved.  The success of this synthesis was 
confirmed by UV-Vis absorption spectral analysis (Figure 3.1). The bands for TNZnPc 
appear at 350 nm and at 700 nm. Usually the Q band (700 nm) of metallated Pcs is sharp but 
the bands are broad for both metallated and unmetallated derivatives due to aggregation. The 
nitro-containing zinc phthalocyanine spectrum showed slight splitting of the Q band and this 
could be due to the strong electron-withdrawing nitro group. After reduction, a bathochromic 
shift occurred to 740 nm due to the negative inductive effect of NH2, and an extra band 
appeared at 450 nm which can be attributed to aggregation of TAZnPc molecules.  
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Figure 3.1: UV-Vis spectra of tetranitro-zinc-pthalocyanine (TNZnPc), tetraamino-zinc-
phthalocyanine (TAZnPc) and tertaamino-phthalocyanine (TAPc). 
 
UV-Vis spectroscopy can be used to characterize the success of the reduction of the nitro 
group to an amine. After dislodging zinc from TAZnPc, TAPc was attained, and the UV-Vis 
spectrum shows a very broad brand in the range 600-800 nm possibly due to aggregation. 
Aggregation of TAPc is further evidenced by the peak around 450 nm.    
The structure of TNZnPc was confirmed further by FT-IR spectroscopy (Figure 3.2). The 
FT-IR spectrum of TNZnPc had two peaks at 3309 and 3080 cm-1 corresponding to the 
aromatic C-H stretches of the phthalocyanine. The peak at 1638 cm-1 can be attributed to the 
C=C macrocycle ring deformation, whereas the peaks at 1531 and 1333 cm-1 were ascribed to 
the nitro groups. The peak at 1615 cm-1 is due to the bending of the N-H groups, and the 
series of peaks seen at 1148, 1109, and 1069 cm-1 belong to the C-H bending (in plane 
deformation), isoindole C-N stretching  and C-N in plane bending, respectively. Upon the 
reduction of TNZnPc to TAZnPc, the peaks at 3300, and 3290 which correspond to stretching 
vibrations of the amino N-H groups and another peak at 1620 cm-1 that is ascribed to N-H 
bending mode, were observed. The disappearance of the peaks at 1531 and 1333 cm-1, that 
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are attributed to the nitro groups, further confirmed the reduction of nitro groups to amino 
groups. A similar FT-IR spectrum was obtained for a metal-free TAPc, with additional N-H 
bending vibrations of isoindole groups.  
Wavenumber (cm-1)
1000200030004000
Tr
an
sm
itt
an
ce
 (%
)
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
TNZnPc
TAZnPc
TAPc
 
Figure 3.2: FT-IR spectra of tetranitro-zinc-pthalocyanine (TNZnPc), tetraamino-zinc-
phthalocyanine (TAZnPc) and tertaamino-phthalocyanine (TAPc). 
 
In an attempt to synthesize rhenium(V)-phthalocyanine complexes through direct metalation 
of metal-free phthalocyanine with rhenium in its perrhenate form, using triphenylphosphine 
as a reducing agent, hydrolysis of a Pc to a phthalonitrile was observed. Pcs are known to 
have high thermal and chemical stability; however, their decomposition under various 
conditions has been reported. Linstead et al. reported the decomposition of FePcs into 
phthalimide in the presence of hot nitric acid or aqua regia [114].  The same result was 
obtained when cold acidic potassium permanganate was used. Hot concentrated H2SO4 
generated both phthalic acid and phthalimide as the hydrolysis products [114]. A CoPc has 
also been reported to undergo photochemical decomposition [115], and it was discovered that 
the C-N bonds of the Pc cleave at early stages hence leading to the dissociation of the Pc 
N-H N-H 
N-O 
N-H 
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[115]. A mechanistic study was carried out on phthalocyanine dyes and it showed that 
different mechanisms of degradation occur and that they are solvent- and oxygen-dependent 
[116]. Herein, we report a novel oxidative hydrolysis of metal-free 2,9,16,23-tetrasubstituted 
phthalocyanines, R4PcH2 (where R = NH2 and NO2), in the presence of ammonium 
perrhenate (NH4ReO4) and triphenylphosphine (PPh3). Firstly, the preparation of the 
respective Pcs was carried out followed by the rhenium-catalysed hydrolysis reaction 
(Schemes 2.2 and 2.3).   
The conversion of the Pcs to phthalonitriles was also confirmed by FT-IR (Figure 3.1). The 
existence of carbonitrile group in the products is evident from the FT-IR spectra obtained, 
e.g. for the hydrolysis product of TNPc a peak was observed at 2240 cm-1. A similar peak (at 
2255 cm-1) was observed in the hydrolysis product of TAPc (Figure 3.3). 
 
Figure 3.3: FT-IR spectra of; (A) tetranitro-phthalocyanine (TNPc) and the hydrolysis 
product (4-nitrophthalonitrile), and (B) tertaamino-phthalocyanine (TAPc) and the hydrolysis 
product (4-aminophthalonitrile). 
 
Single crystals of the decomposition product of TNPc, which were suitable for X-ray 
analysis, were obtained by the slow evaporation of the mother liquor of the synthetic solution. 
The summary of crystal data, data collection and structural refinement parameters for the 
major product are given (Table 3.1). An ORTEP plot of the major product (4-
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nitrophthalonitrile) is shown in (Figure 3.4). The bond distances between C-C, from C11 to 
C16, range between 1.37(9) to 1.39(1) Å which correspond with the average bond length of 
aromatic C-C bonds. The bond lengths C13-C1 and C14-C2, which were 1.4392(14) and 
1.4423(14) Å respectively, are characteristic of C-C single bonds. The short bond distances 
between C1-N2 (1.1392(14) Å) and C2-N3 (1.14392(14) Å) suggest C-N triple bonds as 
expected for nitriles. Some of the bond distances and bond angles are given in Table 3.2. The 
metrical parameters of this compound are the same as those published recently [117].      
 
Figure 3.4: An ORTEP view of the major product of degradation.  
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Table 3.1: Summary of crystal data for the major product (4-nitrophthalonitrile).  
 
Table 3.2: Selected bond length (Å) and bond angles (°) for 4-nitrophthalonitrile.  
 
 
 
 
 
Parameters  4-Nitrophthalonitrile 
Empirical formula C8 H3 N3 O2 
Formula weight (M) 173.13 
Temperature, T (K) 200  K 
Wavelength, Mo Kα (Å) 0.71073 
Crystal system Orthorhombic 
Space group pbca  
a (Å) 12.9000(5) 
b (Å) 9.2880(5) 
c (Å) 13.3068(6) 
α (°) 90.00 
β (°) 108.493(2) 
γ (°) 90.00 
Volume, V (Å3) 1594.36(13) 
Z 8 
Calculated density, ρ (Mg m-3) 1.443 
Absorption coefficient, µ (mm-1) 0.109 
F(000) 704 
Crystal size (mm3) 0.32 x 0.35 x 0.40 
Index ranges -26 ≤ h ≤ 26, -9 ≤ k ≤ 9, -36 ≤ l ≤ 35 
Reflections collected 33940 
Independent  reflections 8648 [R(int) = 0.0734] 
Completeness to Theta= 28.00o 99.9 % 
Max. and min. transmission 0.9657 and 0.8394 
Data/restraints/parameters 8648/0/496 
Goodness-of-fit on F2 0.914 
Final R indices [I>2σ(I)] R1 = 0.0438, wR2 =   0.0871 
R indices (all data) R1 = 0.0870, wR2 = 0.0993 
Largest diff. peak and hole (eÅ-3) 0.552 and -0.355 e.Å
-3
 
Bond lengths  (Å) Bond angles              (°) 
O(1)-N(1) 1.2206(13) O(1)-N(1)-O(2) 124.58(10) 
 O(2)-N(1) 1.2222(12) O(1)-N(1)-C(11) 117.40(9) 
N(1)-C(11) 1.4735(13) O(2)-N(1)-C(11) 118.02(9) 
N(2)-C(1) 1.1394(15) N(2)-C(1)-C(13) 178.17(12) 
N(3)-C(2) 1.1429(14) N(3)-C(2)-C(14) 178.52(11) 
C(1)-C(13) 1.4392(14) N(1)-C(11)-C(12) 118.06(8) 
C(2)-C(14) 1.4423(14) N(1)-C(11)-C(16) 118.54(9) 
C(11)-C(12) 1.3791(13) C(12)-C(11)-C(16) 123.40(9) 
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To further confirm the results of the hydrolysis reactions, GC-MS analysis was carried out. 
The MS results of the purified major product isolated from TNPc degradation showed a peak 
at 173.0 (m/z) which corresponded well with 4-nitrophthalonitrile (Figure 3.5). A peak at 
144.0 (m/z) was also obtained for the crude products of TAPc degradation which was 
ascribed to 4-aminophthalonitrile (Figure 3.6). 1H NMR and 13C NMR were also used to 
further confirm the structures of the phthalonitriles (Figures 3.7 and 3.8) respectively. The 
NMR spectra of both the phthalonitriles is in agreement with known spectral data [118]. An 
attempt to decompose an unsubstituted Pc was discouraged by solubility problems.  However, 
it is worthwhile to note that the hydrolysis reaction is not selective to only phthalonitriles as 
there were many unexplained peaks observed in the MS spectra, and it is thought that some 
of the products coordinate to rhenium. The yields were, however, relatively high for the 
phthalonitriles (58 and 64 %, respectively, for the amino and nitro derivatives). 
 
Figure 3.5: GC-MS spectrum of the clean product obtained upon the hydrolysis of tetranitro-
phthalocyanine (TNPc) with ammonium perrhenate (NH4ReO4) in the presence of 
triphenylphosphine (PPh3).   
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Figure 3.6: GC-MS spectrum of the crude products obtained upon the hydrolysis of 
tetraamine-phthalocyanine (TAPc) with ammonium perrhenate (NH4ReO4) in the presence of 
triphenylphosphine (PPh3). 
-3-2-1012345678910111213141516
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2
3
 
Figure 3.7: 1H NMR spectrum of the hydrolysis products of tetranitro-phthalocyanine 
(TNPc) and tetraamino-phthalocyanine (TAPc). 
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Figure 3.8: 13C NMR spectrum of the hydrolysis products of tetranitro-phthalocyanine 
(TNPc) and tetraamino-phthalocyanine (TAPc). 
The reaction seems to be rhenium(V)-catalysed since it only occurs in the presence of 
triphenylphosphine which is known to reduce Re(VII) to Re(V) and itself converted to 
triphenylphosphine oxide  [119]. The reaction also requires the presence of oxygen since it 
did not occur under a nitrogen atmosphere; hence it is called an oxidative hydrolysis reaction.  
3.3 Rhenium(V)-phthalocyanine complex 
There are very few phthalocyanine complexes with rhenium as central metal that are known 
and these compounds are all quite insoluble in common organic solvents [65]. In the few 
rhenium-phthalocyanine complexes that appear in the literature most of these complexes 
consist of amido group in the axial position [66]. The rhenium-phthalocyanine that possess an 
oxo group in the axial position are very difficult to synthesize due to the steric demand issue 
since the oxo repels the equatorial ligands more [65]. Herein, we report on this synthesis of 
oxo rhenium(V)-phthalocyanine complex.  
4-Nitrophthalonitrile 
4-Aminophthalonitrile 
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3.3.1 Re-TAPc complex 
In this study, Re(V) Pc complex with an oxo ligand in the apical position was successfully 
synthesized by direct metalation of metal-free phthalocyanine from ammonium perrhenate, 
using sodium metabisulphite (Na2S2O5) as a two-electron reducing agent. The reaction was 
carried out in a mixture of n-octanol and water (see Scheme 2.5). The success of this reaction 
was confirmed with the electronic absorption techniques, i.e. UV-Vis together with magnetic 
circular dirchroism (MCD). The UV-Vis spectra of both metal free TAPc and Re-TAPc 
shows the B (soret) band at 360 nm and 318 nm respectively (Figure 3.9). The UV-Vis 
spectrum of TAPc doesn’t clearly show a split Q band at 730 nm as expected for a metal-free 
Pc instead a very broad Q band at 730 nm is observed due to aggregation. After metalation 
with Re, a relatively sharp band is observed at 694 nm suggesting that metalation of TAPc 
was achieved. MCD was used to confirm the UV-Vis results.       
MCD can be employed in the characterization of Pcs since it can also give information on 
electronic transitions, B(0,0) and Q(0,0) bands in the case of the Pcs, due to the presence of 
intense Faraday A1 terms or coupled pairs of oppositely-signed Faraday B0 terms [64]. 
Figure 3.9 reports the MCD spectra of TAPc and Re-TAPc. A very intense B0 term seen 
suggests that the B1 and B2 bands lie in the 300-400 nm range. The major difference between 
the metal-free Pc and metalated Pc is visible in the Faraday A1 term, where a sharp negative 
A1 term appears at 720 nm in the metalated Pc while a band peak is observed with the 
unmetalated Pc at 775 nm. Positive A1 term is observed at 667 nm in Re-TAPc spectrum 
while TAPc spectrum appears to have two bands in the A1 region at 684 and 728 nm.   
FT-IR spectra of TAPc and Re-TAPc are shown in Figure 3.10. The spectra are very similar 
and both show peaks at 3381 cm-1, 3245 cm-1 and 1612 cm-1 that can be ascribed to N-H 
stretching and bending vibrations of amino groups.  
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Figure 3.9: UV-Vis and MCD spectra of (A) tertaamino-phthalocyanine (TAPc) and (B) 
rhenium(V)-tetraamino-phthalocyanine (Re-TAPc). 
 
The oxo-metallates are already known with porphyrin as macrocyclic systems [66] and also 
Ziener et al. reported the synthesis of oxido rhenium(V)-phthalocyanine complexes [66]. The 
synthesis involves the reaction of rhenium pentachloride with phthalonitrile to yield the oxido 
rhenium-phthalocyanine complex. In this study, the oxido complex is obtained using 
ammonium perrhenate directly as a precursor. And this synthesis involves the metalation of a 
pre-formed phthalocyanine instead of the one-pot synthesis reported elsewhere [66]. The 
MCD MCD 
UV-Vis UV-Vis 
A B 
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approach presented herein is an ideal route for radiopharmaceutical preparations since it 
requires one step.  
 
 
Figure 3.10: FT-IR spectra of tertaamino-phthalocyanine (TAPc) and (B) rhenium(V)-
tetraamino-phthalocyanine (Re-TAPc). 
 
3.3.2 Folate conjugation of TAPc and attempted metalation with rhenium   
After the direct metalation of tetraaminophthalocyanine (TAPc) with rhenium, the nex step 
was the conjugation of TAPc with a targeting molecule (folic acid) so as to enhance solubility 
of the Pc and to improve localization of the Re-TAPc complex inside the cancer cells since 
folic acid receptors are known to be over-expressed on some cancer cells [120]. The 
conjugation of TAPc with folate was achieved by the activation of the carboxyl group of the 
folic acid (FA) with N,N’-Dicyclohexylcarbodiimide (DCC) (Scheme 2.4). Folic acid 
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contains two COOH groups; α and γ, which react with amino group via amide bond 
formation. Due to the higher reactivity of the γ-carboxylic acid group as compared to the α-
carboxylic acid, the former is more likely to be activated by DCC [106]. It has also been 
shown with porphyrin-FA conjugates that the amide bond mainly forms on γ-carboxylic acid, 
therefore, in this study it is assumed that conjugation is chiefly through γ-carboxylic acid. 
The UV-Vis spectrum of the FA conjugated TAPc is shown in Figure 3.11, and there is not 
much difference compared with the UV-Vis spectrum of TAPc (see Figure 3.9A). The Q 
band of FA-TAPc is slightly red shifted (740 nm) and the B bands are absorbing almost at the 
same wavelength, i.e. 360 nm and 358 nm for TAPc and FA-TAPc, respectively. The 
spectrum of FA-TAPc also shows a band at 298 nm which could be the pi-transitions of the 
cyclic part of the folic acid [106]. MCD electronic spectrum of FA-TAPc is also similar to 
TAPc spectrum. Two very broad Faraday A1 bands that possess opposite charges appear at 
664 and 763 nm. The B0 term is also within the range 300-400 as in the case of TAPc, 
suggesting that the conjugation with FA doesn’t alter the electronic properties of the Pcs to a 
larger extent.     
 
Figure 3.11: UV-Vis and MCD spectra of folate-conjugated tetraamino-phthalocyanine (FA-
TAPc). 
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Figure 3.12 depicts the FT-IR spectra of FA-TAPc that exhibits peaks at 3336 cm-1 
corresponding to the amino N-H stretch, 2935 and 2853 cm-1 that can be attributed to 
aromatic C-H stretch and 1694 cm-1 that can be ascribed to C=O of the amide group. The use 
of FT-IR to confirm FA-TAPc is complicated owing to the amide bonds that are already 
present on FA, for this reason FT-IR cannot be used to conclusively prove the amide bond 
formation in the case of TAPc. Figure 3.13 shows the mass spectrum of FA-TAPc, and a 
molecular ion at 1017 amu in agreement with 1:1 Pc:FA ratio. This confirmed amidation of 
one of the amine groups in TAPc.      
 
Figure 3.12: FT-IR spectra of tetraamine-phthalocyanine (TAPc), folate (FA) and folate-
conjugated tetraamine-phthalocyanine (FA-TAPc). 
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Figure 3.13: Mass spectrum of folate-conjugated tetraamine-phthalocyanine (FA-TAPc).  
3.4 Rhenium nanoparticles  
As a result of the failure to synthesize folate-conjugated Re(V)-phthalocyanine complex, the 
focus was shifted to the synthesis of folate-conjugated phthalocyanine capped rhenium 
nanoparticles (Re NPs). Application of rhenium isotopes in medicine is a rapidly growing 
field, more especially for imaging and therapy [80]. It is anticipated that combining imaging 
properties of NPs and radioactivity might improve imaging quality of the tumours found deep 
within the tissues [90].  
The NPs size is a very important factor to be considered in medicinal applications. For 
example nanoparticles of sizes between 80 nm and 250 nm exhibit in vivo toxicity due to the 
accumulation of the nanoparticles in the liver and spleen [121]. To overcome the 
shortcomings presented by nanoparticles of larger sizes, nanoparticles with decreased sizes 
stands as a possible solution. For example NPs of the sizes ranging between 10 and 50 nm 
1017.823
0
500
1000
1500
2000
2500
In
te
ns
. [
a.
u.
]
1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
m/z
NH
N
N
N
N
HN
N
N
NH2
NH2
H2N
HN N
N
NO
H2N
NH
NH
O
HO2C
HN
O
S. Ntsimango                                                                                    Nelson Mandela Metropolitan University  
 
C h a p t e r  4   P a g e  | 68 
 
can easily avoid immune activation and renal clearance, therefore improving their circulating 
time and availability for effective therapy [122]. Nanoparticles of sizes between 10 and 50 
nm are small enough to slow down activation of the mononuclear phagocyte system but are 
big enough to avoid renal filtration [123]. Herein, the synthesis of folale-conjugated 
tetraamino-phthalocyanine rhenium nanoparticles of sizes between 5 nm and 50 nm is 
reported.  
The synthesis was carried out in aqueous solution (0.9% saline) so as to mimic the conditions 
in which rhenium is obtained straight from its 188W/188Re generator, with NaBH4 as a 
reducing agent (Scheme 3.1). During the synthesis of Re NPs, when NH4ReO4 was dissolved 
in water together with an acetate buffer, the solution remained colourless however upon the 
addition of NaBH4 the solution changed to tan (Scheme 3.1). The observed change in colour 
is consistent with the formation of colloids [124]. A further change in colour to black was 
observed when the nanoparticle solution was left at room temperature, and that has been 
attributed to the reoxidation of Re nanoparticles [125]. No XPS measurements were carried 
out to confirm the oxidation state of the nanoparticles, due to difficulty in to control oxidation 
of NPs during sample preparation. Mucalo et al. also reported this problem [125,126]. 
However, a simple reaction between perrhenate and sodium borohydride is known to yield 
Re(III) [104,107,127], hence, the formation of Re2O3 nanoparticles is proposed here.      
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Scheme 3.1: Synthesis of folate-conjugated tetraamine-phthalocyanine (FA-TAPc) capped 
rhenium nanoparticles (Re NPs).  
 
To afford nanoparticles of different sizes, the reaction conditions were optimised using three 
variable chemometrics model (23) where conditions such as the amount of the reducing agent 
(NaBH4), metal salt (NH4ReO4) and the capping agent (FA-TAPc) were varied 
systematically. Table 3.3 lists the optimization conditions used to prepare different particle 
sizes. To synthesize rhenium oxide nanoparticles, 100 mM NH4ReO4 solution was prepared 
with ultrapure water (100 mM), FA-TPc solution in DMSO (10 mg/ ml), and 100 mM NaBH4 
was also prepared using ultrapure water.      
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Table 3.3: Various conditions used in the optimisation of Re NPs synthesis. 
 
 
Figure 3.14 shows UV-Vis spectra of folate-conjugated tetraamine-phthalocyanine (FA-
TAPc) capped rhenium nanoparticles synthesised by changing some reaction parameters.  
The surface plasmon resonance (SPR) peak of Re NPs is observed around 380 nm (with the 
exception of SP3 and SP7). The peak is relatively narrow signifying a narrow size 
distribution of the particles. The SPR peak tends to be red shifted when the amount of the 
metal salt is increased and the amounts of the reducing and capping agent are decreased. 
Another very broad peak is observed at 712 nm corresponding to the Q band of the metal-free 
TAPc capped with folic acid. The peak around 712 nm becomes pronounced as the particle 
size increases. The UV-Vis spectra of SP3 and SP7 does not show the SPR peak, this could 
be due to the size in SP7 and reoxidation of SP3 as evidenced in the TEM microgram 
obtained (Figure 3.15).   
Sample code Amount of 
NH4ReO4 
Amount of 
FA-TAPc 
Amount of 
NaBH4 
SP1 60 µL 1000 µL 500 µL 
SP2 80 µL 1000 µL 500 µL 
SP3 60 µL 1500 µL 500 µL 
SP4 80 µL 1500 µL 500 µL 
SP5 60 µL 1000 µL 700 µL 
SP6 80 µL 1000 µL 700 µL 
SP7 60 µL 1500 µL 700 µL 
SP8 80 µL 1500 µL 700 µL 
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Figure 3.14: Optical spectra of folate-conjugated tetraamine-phthalocyanine (FA-TAPc) 
capped rhenium nanoparticles (Re NPs). 
 
Figures 3.15, 3.16 and 3.17 presents the TEM micrograms and particle distribution graphs of 
the FA-TAPc capped Re NPs. The TEM micrograms confirm the results obtained from the 
UV-Vis spectra of the FA-TAPc capped Re NPs, i.e. an increase in the amounts of the metal 
salt and the decrease in the amounts of the reducing and capping agent leads to the formation 
of “larger” NPs and vice versa. TEM images also depict that the particles with smaller sizes 
(SP1, SP4, SP5, SP7 and SP8) assume a noticeable spherical shape while the lager particles 
(SP2 and SP6) show non-spherical shapes and also show poor distribution patterns. The 
particle distribution graph for SP3 could not be obtained since the nanoparticles formed 
superlattices.   
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Figure 3.15: TEM micrograms of folate-conjugated tetraamine-phthalocyanine (FA-TAPc) 
capped rhenium nanoparticles (Re NPs) and their subsequent particles size distributions: SP1, 
SP2 and SP3. 
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Figure 3.16: TEM micrograms of folate-conjugated tetraamine-phthalocyanine (FA-TAPc) 
capped rhenium nanoparticles (Re NPs) and their subsequent particles size distributions: SP4, 
SP5 and SP6. 
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Figure 3.17: TEM micrograms of folate-conjugated tetraamine-phthalocyanine (FA-TAPc) 
capped rhenium nanoparticles (Re NPs) and their subsequent particles size distributions: SP7 
and SP8. 
 
The summary of the SPR absorption of the Re NPs and their corresponding average particle 
sizes are listed in Table 3.4.  
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Table 3.4 Summary of the absorption data of the Re NPs and their corresponding average 
particle sizes.   
 
 
 
 
 
 
 
 
The fluorescence properties Re NPs of sizes 10 nm and 50 nm were studied with a 
spectrofluorimeter to provide information for possible investigation of their cell localization 
ability on cancer cells via confocal fluorescence microscopy studies.  
To understand the fluorescence properties of the rhenium nanoparticles of sizes 10 nm and 50 
nm, the NPs were excited at 350 nm, 405 nm and 488 nm to obtain the fluorescence emission 
spectra. The emission spectra obtained for the two particle sizes were very similar, and 
Figure 3.18 displays emission spectra of 10 nm particles using the abovementioned 
excitation wavelengths. Two emission peaks at 438 nm and 699 nm were obtained from 
excitation at the wavelength of 350 nm. Excitation at 405 nm wavelength resulted in red-
shifted fluorescence emission spectra that are observed at 445 nm and 518 nm. The excitation 
at 488 nm also resulted in a very red-shifted peak at 570 nm; a difference of 132 nm from the 
Sample Code SPR 
Absorption (nm) 
Average 
Particle Size (nm) 
SP1 391 22.85(0.04) 
SP2 396 49.80(0.56) 
SP3   
SP4 383 21.94(0.58) 
SP5 385 7.43(0.31) 
SP6 392 18.66(0.05) 
SP7  3.94(0.08) 
SP8 380 8.63(0.92) 
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350 nm excitation wavelength. Excitation wavelength of 350 nm was used for confocal 
fluorescence studies since it gave narrow emission spectra.     
 
Figure 3.18: Emission spectra of size 10 nm rhenium nanoparticles excited at different 
wavelengths (350, 405 and 488 nm).  
 
UV-Vis and fluorescence emission and excitation spectra of Re nanoparticles are shown in 
Figures 3.19 and 3.20. The fluorescence emission spectra were recorded for the two different 
Re NPs sizes. The spectra were recorded in water. Two fluorescence emission peaks were 
observed at 438 nm and 699 nm, for both particle sizes. 10 nm exhibits elevated fluorescence 
intensity as compared with size 50 nm Re NPs. The peak at 699 nm is due to the Pcs 
fluorescence used as the capping agent. The fluorescence emission wavelength was kept at 
580 nm whilst measuring excitation spectra. The fluorescence of the NPs shows a stokes shift 
of 41nm.  
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Figure 3.19: UV-Vis, excitation and emission spectra of 50 nm NPs  
 
Figure 3.20: UV-Vis, excitation and emission spectra of 10 nm NPs. 
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3.5 Biochemical applications  
3.5.1 Cell cytotoxicity studies  
The use of nanomaterials in various disciplines such as chemical, biomedical and diagnostics, 
etc. has led to multidisciplinary strategies in the design and assembly of smart and stealth 
hybrid materials [128]. These Nanomaterials owe their supremacy to their versatile physico-
chemical properties, which greatly enhances their diagnostic and therapeutic performances 
[129]. Due to their anticipated use, the interactions of nanoparticles with biological systems 
like living cells have encouraged a collaborative research across various disciplines such as 
chemistry, physics, materials and biology [130].  
The best way to investigate cytotoxicity and biological effects induced by the nanomaterials 
can be achieved through the use of in vivo techniques. However, although in vivo techniques 
are very informative they are also inherently expensive and require a lot of preparative work 
[131]. Due to these reasons, in vivo techniques are incompatible for methodical and routine 
biological studies of nanomaterials that are currently being developed. Numerous cell models 
have been developed as a suitable, lucrative and simpler substitute for the cytotoxicity and 
biological responses of nanomaterial [132].  
Consequently, there exists a plethora of literature on in vitro cytotoxicity studies of 
biofunctionalised nanoparticles [82,133,134]. For example Hathaway et al. used targeted 
superparamagnetic iron oxide nanoparticles for the detection of breast cancer cells on Her2 
cell lines [135]. Mukherjee et al. investigated cytotoxicity of Ag nanoparticles on human 
dermal noncancerous (HaCaT) and cervical cancer (HeLa) cell lines [133].  
Various studies that illustrate the behaviour of nanoparticles in the biological systems have 
been done with the aid of confocal fluorescence microscope and other imaging techniques 
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such as TEM. For example Gliga et al. investigated the cell-uptake of silver nanoparticles 
uptake and intracellular localization in human lung cells using transmission electron 
microscopy (TEM) [136]. Jin et al. employed confocal fluorescence microscope to 
investigate the specific uptake of epidermal growth factor (EGF) conjugated nanoparticles in 
lung cancer cells [137]. Despite the abundant literature on cell localization studies of various 
nanoparticle systems, there is a lack of information on the cell-uptake and cell accumulation 
studies on rhenium nanoparticles. 
In this study three different cancer cell lines MDA-MB-231, HCC70, HCC1806 that exhibit 
low, medium and high folate receptors (FR), respectively and normal cell line (HEK) were 
employed in the cytotoxicity investigations. The aim was to establish the concentrations that 
show high cell viability (i.e. non-cytotoxic concentrations), since the cells will allegedly be 
destroyed by radiation. The viability profiles of dose-dependent, size-dependent and 
bioconjugation towards cytotoxicity evaluation of Re NPs are shown in Figures 3.21 and 
3.22. The profiles of FA, methanol (the dispersion solvent), paclitaxel PTX (as the positive 
control) and untreated cell lines (as negative control) are also documented in the above-
mentioned figures.  
For dose dependent responses, the cell survival rate of the different Re NPs obtained from 
varying concentrations (500, 50, 5, 0.5 and 0.005 µM) showed mixed results for all cell lines, 
but generally they show a slight decrease in cell viability with the increase in the 
concentrations of the test materials (Figures 3.21 and 3.22). Cell survival rate was more than 
80% for all the concentrations, meaning all the concentrations could be used for cell uptake 
studies.   
For bioconjugation dependent investigation, similar results were obtained for all different 
cancer cell lines including the normal cell line upon exposure to FA-TAPc capped Re NPs. 
S. Ntsimango                                                                                    Nelson Mandela Metropolitan University  
 
C h a p t e r  4   P a g e  | 80 
 
There is no clear pattern in the evaluation of size dependent response of the two different 
sizes containing the same capping agent. Size-dependent cytotoxicity studies of different 
nanoparticle systems have also been done in the literature and the results are still unclear 
[122]. 
  
 
Figure 3.21: Cytotoxicity profiles of FA-TAPc capped Re NPs (sizes 10 nm and 50 nm), 
uncapped Re NPs, FA, MeOH and PTX on (A) HCC7 and (B) HEK cell lines. 
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Figure 3.22: Cytotoxicity profiles of FA-TAPc capped Re NPs (sizes 10 nm and 50 nm), 
uncapped Re NPs, FA, MeOH and PTX on (C) MDAMB231 and (D) HCC1806 cell lines. 
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3.5.2 Cell  uptake studies 
3.5.2.1 Confocal microscope  
Cell localisation ability of the Re NPs was investigated using confocal fluorescence 
microscope. This technique takes advantage of the fluorescence properties of the Re NPs, as 
they were proven to be exhibit fluorescent properties. The cells treated with FA and MeOH 
show slight fluorescence (Figure 3.23B and C).  FA is known to exhibit fluorescence 
properties [138]. The Re NPs, bare and FA-TAPc capped were internalized as evidenced in 
Figure 3.23D, E and F. The results were analysed using ZEN blue software. The intensity of 
the fluorescence, however, differs for different nanoparticle systems. For example, the 
intensity of uncapped Re nanoparticles (size 50 nm) is low relative to that of 50 nm FA-TAPc 
capped Re NPs, and 10 nm particle size exhibits the highest intensity. This could be due to 
the particle size effect because particles of smaller sizes exhibit good fluorescence properties 
as compared to “bigger” nanoparticles of the same material. The high fluorescence intensity 
on 10 nm treated cells could also be due to higher concentrations of size 10 nm NPs that are 
internalised in the cells.     
To exclude the possibility that the NPs were adhered on the surface of the cells and not 
internalized, zstacks of the cells were performed using ZEN blue software. The zstack option 
sections the cell, to track exactly which depth of the cell exhibit the fluorescence materials 
(NPs in this case). The cells were sectioned into 1 µm, the zstack of 10 nm Re NPs is shown 
in Table 3.5. Confocal fluorescence microscope shows that the NPs were internalized since 
the fluorescence was only detection deep inside the cell, and the maximum intensity was 
observed at the depth of 12 µm. A similar trend was observed with the bare Re NPs and 50 
nm Re NPs.  
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Figure 3.23: Confocal fluorescence images of HCC1806 cell lines treated with: (A) Hoechst 
33324 nuclear stain, (B) Folic acid, (C) Methanol, (D) Uncapped Re NPs, (E) 50 nm Re NPs 
and (F) 10 nm Re NPs. 
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Table 3.5: Zstack results obtained on 10 nm FA-TAPc capped Re NPs. 
Depth (µm) Phase contrast-fluorescence 
microscopic images 
Normal cell view 
1 
  
4 
  
8 
  
12 
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Table 3.5: Continued.   
16 
  
20 
  
24 
  
 
3.5.2.2 Intracellular localization of Re NPs investigation with TEM   
Intracellular localization of Re NPs in HCC1806 cells was examined with TEM. The same 
procedure was followed as in the preparation of cytotoxicity investigation with confocal 
fluorescence microscope (Section 2.3.9). The cells were exposed to Re NPs for 6 h followed 
by chemically fixed with glutaraldehyde so as to fix the major cellular components in place. 
OsO4 was used as the secondary fixing reagent and it also act as the contrast enhancing 
reagent since most biological substances exhibit low contrast under electron beam from 
TEM.   
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The cells were dehydrated with various reagents (see Table 2.3). Subsequently, the cells were 
embedded on a resin so as to cut cell sections since cells are “too big” to be viewed under the 
TEM. Ultra microtome was used to cut the cells into 80 nm sections. The cell sections were 
placed under TEM. The TEM micrograms obtained for the Re NPs are shown in Figures 
3.25 to Figure 3.27.   
TEM images of untreated cells show no morphological alterations and there are no 
nanoparticles observed as expected (Figure 3.24). 10 nm Re NPs exhibits better localisation 
patterns than 50 nm and bare Re NPs as suggested by the confocal fluorescence studies. Size 
10 nm NPs also show quite a number of cells that are not internalised (Figure 3.26), since the 
cell lines were washed before fixing, this could mean the NPs were inside the cells during 
washing and exited the cell afterwards. The 50 nm Re NPs also showed particles of 20 nm 
nanoparticles in addition to the 50 nm particles (Figure 3.25). This could be due to instability 
of the Re NPs under physiological conditions resulting in the breakdown of the particles. The 
cell lines for uncapped Re NPs were not properly fixed, but they still show tumour cell 
localization to some extent (Figure 3.27).    
 
 
Figure 3.24: TEM images of cell sections treated with MeOH, (A) a full cell view and (B) a 
closer view (zoomed). 
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Figure 3.25: TEM images of cell sections treated with 50 nm FA-TAPc capped Re NPs, (A 
and C) a full cell view and (B and D) a closer view (zoomed).  
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Figure 3.26: TEM images of cell sections treated with 10 nm FA-TAPc capped Re NPs, (A 
and C) a full cell view and (B and D) a closer view (zoomed). 
 
 
Figure 3.27: TEM images of cell sections treated with uncapped Re NPs, (A) a full cell view 
and (B) a closer view (zoomed). 
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Chapter 4 
….. 
Conclusions and future work 
4.1 Conclusions 
This dissertation details the investigation involved in an attempt to synthesize rhenium(V)-
phthalocyanine complexes, using Re from the oxidation state of +7, in the presence of 
different two-electron reducing agents (PPh3, Na2S2O5 and NaBH4). Subsequently, different 
results were obtained, such as the hydrolytic cleavage of the Pcs, Re Pc complex formation 
and phthalocyanine capped Re nanoparticles. For the best part, the work focused on Pc 
capped Re NPs. The Pcs were biofunctionalised with folic acid to enhance solubility and 
targeting ability of the Re NPs. Finally, both cytotoxicity and cell-uptake studies of the 
nanoparticles were carried out. In short, the conclusions that were reached in the study are 
further listed below: 
Oxidative hydrolysis of the phthalocyanines: The synthesis and characterization of amino 
(―NH2) and nitro (―NO2) tetrasubstituted metal-free phthalocyanines was described. An 
attempt to directly metalate meta-free Pcs with Re(VII) to form Re(V)-Pc complexes in the 
presence of triphenylphosphine (PPh3) as a reducing agent resulted in the hydrolysis of the Pc 
to its phthalonitrile precursors. The reaction seems to be rhenium(V)-catalysed since it only 
occurs in the presence of triphenylphosphine. The reaction occurs in the presence of oxygen 
and not under nitrogen atmosphere; hence the oxidative hydrolysis of pthalocyanines is 
suggested. The study has shown that phthalocyanines can be decomposed with rhenium(V) 
(produced by reduction of perrhenate with triphenylphosphine) via oxidative hydrolysis.  
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Rhenium(V)-phthalocyanine complex: The successful synthesis of Re(V)-Pc complex via the 
direct metalation of Pcs with Re(VII) was achieved through the use of sodium metabisulphite 
as the reducing agent. The success of the reaction was confirmed with spectroscopic 
techniques such as UV-Vis and MCD. It is worthwhile to note that further optimization of the 
synthesis to improve the yield and single crystal X-ray characterization of the complex is still 
needed. The complex is insoluble in most solvents. An attempt to extend the synthesis of 
Re(V)-Pc to folic acid conjugated phthalocyanines was not successful, the bioconjugate (FA) 
tends to be cleaved from the Pc.  
Rhenium nanoparticles: Upon employing sodium borohydride as a reducing agent, rhenium 
nanoparticles that are capped with the phthalocyanines were obtained. The nanoparticle 
synthesis was further explored and refined to yield NPs of narrow size distribution and 
defined shapes. Owing to their intended application Re NPs were capped with folic acid 
conjugated phthalocyanines; the synthesis was done in an aqueous saline medium. The 
nanoparticles were characterised with UV-Vis and TEM, no XRD measurements were carried 
out, due to difficulty in obtaining the nanoparticles in significant quantities in a solid form. 
The synthesis was proven to be highly reproducible. 10 nm and 50 nm particles sizes were 
envisaged as suitable for applications in biological systems, and their fluorescence properties 
were studied to provide information for possible investigation of their tumor localization 
using human cancer cells via confocal fluorescence microscopy studies.   
Biological studies: Owing to their anticipated use, the inherent biologic effects of the 
rhenium nanoparticles were studied. The studies were performed to establish some biological 
responses that are induced by these NPs through a series of cancer cell lines with varying 
amounts of receptors that are over expressed for folic acid. Cytotoxicity investigation of the 
Re NPs (10 nm and 50 nm) was done on HCC7, HCC1806, HEK and MDAMB231 cells 
lines. Mixed results were obtained for all the cell lines, but generally they show a slight 
S. Ntsimango                                                                                    Nelson Mandela Metropolitan University  
 
C h a p t e r  4   P a g e  | 91 
 
decrease in cell viability with the increase in the concentrations of the test materials, although 
a cell survival rate above 80% was maintained for all the cell lines. The size and 
biofunctionality effects were also compared.   
Cell uptake studies were also conducted on HCC1806 cell line using confocal fluorescence 
microscope; the results obtained were confirmed with TEM. Generally the NPs did enter 
through the cells, with size 10 nm particle size showing better results than 50 nm, while bare 
NPs shown poor cell uptake results. This suggests that the targeting bioconjugate (FA) does 
enhance cell accumulation of the NPs.   
4.2 Future work 
The FA-TAPc conjugated Re NPs will be taken further for tumor and organ biodistribution 
studies using micro-SPECT kits and model mice (using the “hot” isotopes in a radiopharmacy 
laboratory). 
 Despite the successes witnessed in the study, there are still some gaps that still need to be 
addressed. For example synthesis would need to be revisited to achieve more uniform size 
distribution. Another possibility is the introduction of different diamines such as 
ethylenediamine or benzene-1,4-diamine (see the Figure 4.1 below), due to the complications 
in the purification of amine substituted phthalocyanine and the possibility of various side-
products during bioconjugation. The stability of these NP systems also needs to be 
investigated. 
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Figure 4.1: The proposed structure of rhenium nanoparticles that are capped with 
ethylenediamine conjugated with folic acid. 
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